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Ovarian hormone fluctuation has been associated to clinical status of several autoimmune 
conditions and the influence on inflammatory disease is under investigation. The 
incidence of inflammatory bowel disease is high in the West and rising in other parts of 
the world. Immunomodulating treatments are available but there is a need for a cheap, 
readily available treatment with an enhanced risk-benefit ratio. The effect of estrogen and 
progesterone receptor mediated signaling on the immune response of myeloid cells, such 
as monocytes or macrophages have been studied to some extent with varying results. In 
addition to ovarian hormones, selective estrogen receptor modulators have also been 
suggested to modulate inflammatory response of several types of immune cells. In this 
master´s thesis project, small interfering RNA-based receptor silencing was used to 
investigate the immunomodulatory effect of ERα and PGR signaling as well as to 
illuminate the molecular mechanism of SERM2, a novel compound. Further, the aim was 
to gain information for the development of hormone receptor mediated 
immunomodulatory treatment of autoimmune or inflammatory disease. The results 
indicate suppression of monocyte NF-κB activation by PGR signaling, while the ERα 
mediated signaling had a very varied effect. It is possible that ERα upregulation increases 
the proinflammatory potential of monocytes. Cytokine expression analysis of both cell 
line and primary monocytes exhibited modulation of inflammatory cytokines by PGR 
mediated signaling, which possibly could reduce the activity of Th17 cells in the gut, 
while the opposite could be true regarding ERα upregulation.   
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Traditionally, estrogen receptors (ER) and progesterone receptors (PGR) have been 
considered to mediate signaling in reproductive and mammary tissues. There, indeed, the 
main regulatory effects, such as proliferation of the mucosa, secretion and follicle 
maturation are executed. However, these receptors are also expressed in other tissues such 
as skin, neural, vascular, bronchial and intestinal tissues as well as in several types of 
immune cells. Enzymes involved in the synthesis of estrogen are also expressed in non-
reproductive tissues, such as brain, adipose tissue and the skin. In females, after puberty, 
the ovaries are the main producing tissue of the lipophilic hormones, secreting estrogens 
and progesterone systemically. Non-reproductive ER and PGR signaling vary and be 
tissue specific, due to differential expression patterns of receptor types and other 
regulatory proteins.  
Pro- and anti-inflammatory mechanisms play part in physiological hormone regulated 
processes, such as ovulation (Bouman et al., 2005) menstruation, pregnancy and labor 
(Gomez-Lopez et al., 2010). These processes have also been associated to disease status 
in autoimmune diseases (Oertelt-Prigione, 2012). Gender influences the incidence of 
several diseases, with a higher rate of women suffering of autoimmune disease such as 
multiple sclerosis (MS) or systemic lupus erythematosus (SLE) (Angum et al., 2020). 
Additionally, the outcome of sepsis differs between sexes: the mortality rate is higher in 
men  (Nasir et al., 2015). It has been suggested that the adaptive immune function is 
increased in women, with a possibility of differences also in innate responses (Ngo et al., 
2014). Amongst other things, ovarian hormones are thought to be involved in this 
phenomenon (Rubtsova et al., 2015).  
A famous example of the complexity of hormone immune regulation is the effects of 
estrogens in the disease course of MS, which has T cell mediated neuroinflammatory 
pathophysiology. High estrogen conditions, like pregnancy, have been observed to be 
protective. On the other hand, the post-partum period has been associated with increased 
risk of relapse, hence the investigation of estriol as a potential therapeutic of MS (Gold 
and Voskuhl, 2009). Interestingly, the disease modulating effects of physiological 
hormone fluctuation or hormone replacement therapy can vary significantly by disease 
pathophysiology: in SLE, which is a B cell mediated disease, pregnancy as well as 
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hormone replacement therapy are associated with aggravated disease (Kassi and 
Moutsatsou, 2010).  
Gender and hormonal status may affect inflammatory conditions such as inflammatory 
bowel disease. Hormonal fluctuation has been observed, for instance, to influence the GI 
transit time even in healthy females. In inflammatory bowel disease (IBD) a cyclical 
pattern of symptoms has been reported, as reviewed by (Bharadwaj et al., 2015). As 
prevalence of these inflammatory diseases are on the rise especially in Third World 
countries (GBD 2017 Inflammatory Bowel, Disease Collaborators, 2020), there is a need 
for an affordable, readily available and well-tolerated treatment of these long-term 
diseases. Selective estrogen receptor modulators (SERM) could prove a convenient 
alternative. However, especially since the experimental reports of ER and PGR signaling 
in intestinal inflammation have not been consistent, this controversy needs additional 
attention in order to illuminate underlying mechanisms.  
In this thesis project the possibility of downregulating the monocyte immune response by 
ovarian hormone receptor signaling is explored. Further, the aim is to illuminate the 
receptor mechanism of the anti-inflammatory effects of SERM2 previously reported by 
our research group in human CD14+ cells  (Polari, Lauri et al., 2018) and in a mouse 
model of colitis  (Polari, L. et al., 2019). The experimental focus is on the immune 
response of monocytes by analysis of a nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) activation model as well as by cytokine expression in both 
THP1 cell line monocytes and adult human primary monocytes. This can be valuable 
information in developing novel therapeutics. A specific interest in this project was the 
selective hormone receptor modulators (SHRMs). While searching for new ways to 
alleviate inflammatory disease through the modulation of ovarian hormone receptor 
signaling, one must realize steroid hormone therapy, including natural or synthetic 
estrogen of progesterone analogues, may not be the best option. Especially estrogen 
therapy increases the risk of deep vein thrombosis and cancer in estrogen sensitive tissues. 
SHRMs induce partly similar effects as hormones but have a more specific way of binding 






1.1. Ovarian hormones 
Estradiol (E2) is the predominant estrogen in circulation, while estriol (E3) and estretrol 
(E4) are associated with pregnancy and estrone with the menopause. Ovarian hormones 
are regulated by the hypothalamus-pituitary-gonadal (HPG) axis, in which the kisspeptin‒
neurokinin B‒dynorphin and gonadotropin release hormone (GnRH) producing neurons 
in the hypothalamic infundibular nucleus stimulate the anterior pituitary to produce 
luteinizing hormone (LH) and follicle stimulating hormone (FSH). GnRH, LH and FSH 
can be released in pulses or surges, and pulse frequency regulate the cycle. Rapid GnRH 
pulses induce LH, while slower pulses induce FSH. The HPG axis and ovarian hormones 
regulates development, induce female traits and reproductive processes but also influence 
metabolism, olfaction, mood and cardiac function. Several feedback mechanisms regulate 
the axis. 
During ovarian steroidogenesis, estrogen inducing LH and progesterone inducing FSH 
stimulate enzyme expression in follicular theca and granulosa cells, the final products 
being estrogens, progesterone and small quantities of androgens. The final reaction of 
androstenedione to estrone (E1) and estrone to estradiol, catalysed by aromatase and 17β-
HSD, respectively, takes place in granulosa cells. E2 peaks at and induces ovulation. 
Progesterone is released by the corpus luteum and peaks after ovulation, during the luteal 
phase of the cycle. Chorionic gonadotropin induced progesterone also has an important 
role in maintaining pregnancy. 
1.2. Estrogen receptor signaling 
This thesis will be focusing mainly on ERα, transcribed by ESR1 and second, on PGR, 
transcribed by PGR. The estrogen hormones, estradiol, estrone, estriol (E3) and estretrol 
(E4) have unique affinities to estrogen receptors. The nuclear ERs are divided into 
subtypes ERα and ERβ. E2 binds to ERα at a picomolar to low nanomolar range and to 
ERβ at almost similar affinity (Blair et al., 2000) (Yoo and Jeung, 2009). Apart from 
nuclear receptors, GPER1 is located at either the cell membrane (Martínez-Traverso and 
Pearl, 2015) the endoplasmic reticulum (Revankar et al., 2005) or in some cancers, the 
nucleus  (Samartzis et al., 2014). Thus, estrogen receptor signaling can exert both rapid 
and long-lasting responses. Slow, long-lasting estrogen response is mediated by nuclear 
ER effect on gene expression while, in addition to the G Protein-Coupled Estrogen 
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Receptor 1 (GPER), rapid, nongenomic responses are mediated through the plasma 
membrane bound ERα isoforms.  
ERα is known to be alternatively spliced in at least five ways, producing the full-length 
nuclear receptor ERα66 and amongst others, the cytosolic splice variants ERα46 (Flouriot 
et al., 2000) and ERα36 (Wang et al., 2006) (table 1). The homo- or heterodimer receptor 
is activated by serine phosphorylation at ligand binding, followed by disengaging 
corepressor proteins, which allows nuclear translocation and complexing with 
coactivators. Besides the genomic and non-genomic effects, ligand-independent signaling 
has been seen in cancer, for instance as crosstalk to insulin-like growth factor or epidermal 
growth factor signaling (Hewitt, S. C. et al., 2017). Physiological and immunological 
effects of these hormones and their receptors are  a result of interplay. 
 
 
1.3. Structure and function of ERα  
The full length nuclear ERα (or NR3A1) is large protein with six domains (A-F). The N-
terminal A/B domain is very flexible, allowing it to interact with several coactivator 
proteins, due to intrinsically disordered regions. The DNA binding domain function in 
estrogen response element (ERE) palindrome recognizing and dimerization (C) and 
ligand binding (E) (Hewitt, Sylvia C. and Korach, 2018), represented in figure 1. In the 
inactive conformation or in the absence of coactivators, α-helix 12 (H12) of activation 
function (AF) -2 binds to a LXXLL motif in the ligand-binding domain. H12 changes 
conformation upon agonist binding, being competitively displaced by coactivators 
(Farooq, 2015) (Yaşar et al., 2016). N-terminal AF-1 and FF-2 transactivate and together 
form an interface for coactivator binding (Tora et al., 1989). Transcriptional intermediary 
factor 2 (TIF2) and members of steroid receptor coactivator-1/p160 family have been 
recognised as binders to the AF motifs (Benecke et al., 2000), as have p300-CREB 
binding protein coactivator family members  (Kobayashi et al., 2000) and various heat 
shock proteins (Dhamad et al., 2016).  
Table 1. Structural features of ERα splice variants.  
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In the classical estrogen receptor signaling pathway the transcription complex binds to 
DNA at specific consensus estrogen-response elements. A second, tethered pathway 
exists, where ER participates in complexes also at non-consensus estrogen response 
elements. ERα binds EREs with greater affinity compared to ERβ, and ERαβ 
heterodimers induce a different response compared to ERα homodimers (Powell et al., 
2012). The transcription initiation functions of EREs feature not only reproduction and 
proliferation associated genes, but also genes with, for instance, metabolic and 







Structural differences accounts for differences in the response. There is low homology 
between ERα and ERβ in the protein-interaction interface forming A/B (18%) and F 
domains (17%) (Yaşar et al., 2016). The F domain is also less conserved between species 
Figure 1. Schematic representation of ERα dimer. The full length nuclear ERα has six domains (A-F). 
The terminal A/B as well as E/F domains functions in forming interface for protein interactions while the C 
domain binds DNA. Ligand binding changes the conformation of α-helix 12, enabling the forming of an 
interaction surface for coactivator, such as TIF2, binding. Picture created with BioRender.com 
 
Table 2. Examples of genes transcribed under estrogen-response elements. Adapted 




and has been suggested to play a part in the species-specific differences in SERM 4-
hydroxytamoxifen induced activity (Arao, Y. and Korach, 2018).  
Cytosolic localization for the truncated variants of ERα are complexed beneath the plasma 
membrane and in the mitochondria. Mitochondrial localization is seen especially in 
endothelial cells, where ERα isoforms seem to regulate some mitochondrial genes and 
play a part in preventing apoptosis and ligand-independently in the rescue after 
mitochondrial inter-membrane space stress (Yaşar et al., 2016). Membrane localization 
is enabled by specific serine residue interaction either directly or indirectly with scaffold 
protein caveolin-1 at caveolae rafts and more importantly by palmitoylation of a specific 
cysteine residue is known to be necessary for membrane localization (Acconcia et al., 
2005).  Membrane ERα can signal rapidly by activating protein kinase signaling pathways 
and may colocalize with G-protein coupled receptors. E2 downregulates palmitoylation 
of ERα  (Adlanmerini et al., 2014), one would assume as a negative feedback mechanism 
to inhibit overactivation of the pathway.  
Nongenomic ER signaling is associated to endothelial and cardiovascular protective 
effects (Chambliss et al., 2010) and this comprises also innate immunity ER response, 
which will be discussed in greater detail in sections 1.8-1.10. In short, reports have been 
made of the effects of specifically nongenomic ER signaling in immune cells. These 
include Ca2+ oscillations and both Akt and ERK phosphorylation in murine splenic T cells 
(Ádori et al., 2010), inhibitory crosstalk of ERα36/GPER affecting interleukin (IL)-6 
production in human monocytes (Pelekanou et al., 2016) and that human monocytes and 
macrophages express ERα46 in an estradiol dependent manner  (Murphy et al., 2009). 
Some indications of SERMs inducing non-genomic response can also be found. For 
instance, raloxifene (RAL) was seen to induce the rapid vasodilation response in 
endothelial cells via the phosphoinositide 3-kinase (PI3K) pathway and the effect was 
blocked by fulvestrant (ICI) (Simoncini et al., 2002). 
The genomic signaling has been  suggested to be dominant in the proliferative response 
in the uterus, and that non-genomic effects are associated only to cell-types not utilizing 
the nuclear pathway and that non-genomic response is not able to modulate the genomic 
response (Hewitt and Korach, 2018). However, differing information can be found 
regarding the tissue specificity of nongenomic ER effects. For instance, a palmitoylation 
site mutant mouse was generated to distinguish between nuclear and cytosolic ERα 
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signaling in vivo. These mice were found to have intact uteri, but aberrant ovaries and 
decreased progesterone hormone levels and a lack of E2 induced rapid vasodilation by 
eNOS activation (Adlanmerini et al., 2014). In other pre-clinical models, specific 
pharmacological activation of cytosolic ERα signaling showed no proliferative effects in 
the uterus of mice, nor in hormone sensitive breast cancer xenografts (Chambliss et al., 
2010). However, recent research has implicated a role of cytosolic ERα36 in breast cancer 
progression, and in resistance to anti-estrogen therapy  (Pagano et al., 2020). 
1.4. Regulation of estrogen receptor activity 
The cellular and tissue response to estrogen induced activation is regulated in a complex 
manner; the expression of the receptor is influenced by chromatin related mechanisms, 
post-transcriptional mechanisms, post-translational modifications, localization, 
hormones and growth factors as well as by diverse protein-protein interactions. There are 
several ER promoters in the genome, and the methylation pattern induce ER transcription 
in a tissue and situation dependent manner (Yaşar et al., 2016). ER dimerizes, 
transactivates and forms a heterogenous population in the cell. ERα/ERβ expression ratio 
and homo- vs heterodimerization alters the estrogen response, as αβ heterodimers share 
some of the transcriptional effects as either homodimer, but not all. The αβ heterodimer 
have been indicated to have antiproliferative effects, and the ERβ homodimer might be 
subjected to increased turnover (Chakraborty et al., 2012).  
Dimer type and ligand influence the type of recruited interaction partners, and further, 
ligand affinity to the ER do not always correlate with the level of transcriptional response 
(Routledge et al., 2000). PTMs, such as, but not limited to, phosphorylation by several 
kinases can further induce variation on the protein-protein interaction networks leading 
to gene expression (Treviño and Weigel, 2013). Corepressors can bind the inactivated 
receptor, but the proteins can also inhibit transcriptional function by binding directly to 
DNA or by binding to activated ER complexes and for instance, interacting with 
nucleosome structure and histone altering enzymes (Fuentes and Silveyra, 2019). The 
genomic response element sequence also influences the composition of the transcription 
complex  (Hall et al., 2002).  
At least in mammary and reproductive tissues, in a normal setting, negative feedback 
inhibits overactivation of the pathway: ERα activation induces rapid ubiquitylation and 
proteasomal degradation of the receptor proteins, after which transcriptional upregulation 
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restores the cell to basal level. Binding of antagonist have been seen to increase turnover 
of ER protein but fail to increase the transcriptional response. Cells can also regulate ER 
responses by altering the levels of the co-activating or co-inhibiting molecules, and 
downregulation of ER corepressors has been associated with tamoxifen resistance in 
breast cancer (Légaré and Basik, 2016). Activation of ERβ isoform 2 regulates the 
expression of ERα trough proteasomal degradation (Zhao et al., 2008). Also, ERα induces 
PGR expression  (Xu et al., 2004) and PGR and hCG (possibly also androgen and vitamin 
D receptor) activation downregulate ER expression, while GnRH regulate ER expression 
in a tissue dependent manner (Pinzone et al., 2004). 
1.5. The progesterone receptor 
Progesterone signals mainly via the nuclear PGR, which is expressed at least in ovaries, 
uterus, mammary tissue and in neuroendocrine tissue. PGR protein is transcribed as two 
isoforms under two promoters: truncated PGR-A and full-length PGR-B. These are 
thought to be expressed in distinct tissues and can induce transcription as dimers and 
convey extranuclear signaling as monomers, at least in breast cancer cells (Dressing, G. 
E. et al., 2009). Much like the GPER, progesterone can also signal through membrane G-
protein coupled receptors PGRMC1 and PGRMC2 which convey rapid signaling (Pru 
and Clark, 2013). Progesterone receptor signaling regulate cell growth and differentiation 
and the effect is tissue specific.  
PGR, as ERα, has two flexible AF domains which are conformationally activated by 
ligand binding and dimerization. The AFs, N-terminal AF-1 and LBD located AF-2, 
including H12, are involved in the interaction surfaces for binding coregulator proteins, 
such as p300, and transcription factors. The availability of the transiently interacting 
proteins varies between developmental stage and tissue. The protein complexes bind to 
progesterone response elements in the genome and activates transcription. PGR is 
regulated by several post-translatory modifications, of which some are hormone 
influenced. MAPKs, CDKs and PKA are known to phosphorylate PGR and modifications 
of specific residues can modulate the function and influence the genes transcribed 
downstream PGR activation. Progesterone induced SUMOylation suppresses 
transcriptional effects and provides negative feedback. PGR A signaling suppresses PGR 
B. Additionally, PGR induced miRNAs target mRNA of proteins involved in cell cycle 
progression, thus counteracting proliferation. (Grimm et al., 2016) 
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1.6. Selective estrogen receptor modulators  
SHRMs are pharmacological modulators of the ERs, PGRs or AR. SHRMs are usually 
large lipophilic molecules, which induce a mixed agonist/antagonist response at the target 
receptors. Selective estrogen receptor modulators are a group of compounds targeting the 
estrogen receptor E2 binding site, competitively inhibiting the agonist binding (described 
in figure 2). The large hydrophobic sidechain of SERM molecules (fig 2a) influence the 
conformation, most often inducing repression of transcription or transcription initiated 
under a different set of response elements. SERMs are used as prevention or treatment of 
for instance osteoporosis or ER-positive breast cancer (table 3). 
 
 
SERMs target ERs in a tissue selective manner as partial agonists or antagonists, except 
ICI, which is a full ER antagonist. RAL binds to ERα at levels similar to E2 (Rey et al., 
2009). RAL has been suggested to have a weaker affinity to ERα46 compared to ERα66, 
while estradiol bound each with an equal affinity (Lin et al., 2013).   
The displacement of H12, mentioned earlier to be crucial for ER forming the transcription 
complex, is either in part or fully inhibited from adopting agonist conformation when a 
SERM is bound, due to the large, hydrophobic side chain (fig 2b). After the binding of a 
mixed agonist/antagonist, a switch to agonist conformation can occur as tissue specific 
levels of coactivators increase (Farooq, 2015). Partial agonists might induce a flexible 
conformation, with a slight bias towards antagonism, allowing other protein-protein 
interactions to influence the conformation in tissues which favor activation  (Chakraborty 
et al., 2013). Binding of 4-hydroxytamoxifen, for instance, unwinds helices 3 and 11 
which causes the antagonist conformation of H12 to inhibit the binding of coactivators to 
the nearby ligand-binding cleft LXXLL motif, unless the tissue specific coactivators have 
Table 3. Commonly used SERMs. 
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the ability to replace it (Farooq, 2015). Negative charge of the D351 residue located in 
AF-2 domain has been shown important for RAL and 4-hydroxytamoxifen agonist 
activity in silico (fig 2c). The shape of the aspartate sidechain along with a short 2.7Å 
hydrogen bond is suggested to be important for antagonist activity, since it would distort 
the piperidine ring to shield the negative charge which would be important to cofactor 
binding of AF-2 (Liu, H. et al., 2002) (MacGregor Schafer et al., 2000).  
Besides coactivator expression, the predominance of either ERα or ERβ might be a factor 
determining the agonist/antagonist activity and binding to specific genomic RAL 
response elements (fig 2d) (Rey et al., 2009). The F domain-AF-1 interface is possibly 









Figure 2. The agonist or 
antagonist conformation 
induced by hERα ligands and 
the structure-related effect on 
compiling the transcriptional 
complex. A. Overlay image of E2 
and tamoxifen, showing the large 
hydrophobic sidechain which is 
responsible for the antagonist 
effects. Image public domain via 
Wikimedia commons. B. The 
agonist conformation of ER H12 
(cyan) induced by agonist (left) 
allows the forming of an 
interaction interface and binding 
of coactivator proteins, such as 
TIF2, to the LXXLL motif. An 
antagonist competitively inhibits 
the binding of hormone (right). 
The large side chain induces 
antagonist conformation of H12 
causing it to block the LXXLL-
coactivator interaction. Image 
public domain via Wikimedia 
commons, Boghog2. C. The 
binding site amino acid 
composition influence the 
docking of SERM raloxifene, 
changing the orientation of the 
large side chain. Image: Liu et al 
2001. C. A simplified example of 
SERM raloxifene effect on ERα 
mediated gene expression. Ligand 
differences induces changes in 
complex formation and response 









The novel SERM2 compound used in this project also binds to ERβ and PGR, but neither 
the glucocorticoid receptor nor the androgen receptor. Affinity was measured using a 
radioligand binding assay, resulting in a 50% of maximum binding at <1nM  for ERα, 13 
nM for ERβ and 210 nM for PGR (Polari et al., 2019).  
As the conformation of the ligand bound receptor is defined by the interacting proteins, 
the response can vary greatly. If the protein-interactions, thus the response could be 
induced with even greater specificity, this could possibly be utilized to develop more 
specific receptor modulators to the benefit of various patient groups. Illuminating the 
mechanisms of ER and PGR mediated immune effects could, albeit being an arduous 
task, in best case further the development of an ovarian hormone receptor specific 
immune supporting therapy. Tissue and receptor type specific ER signaling could benefit 
also cardiovascular and possibly cancer patients. Allosterically modulating the receptor 
conformation or the flexible protein-protein interfaces could also prove an interesting new 
treatment option. 
1.7. The innate immune system and the monocyte/macrophage lineage 
The innate immune system is the first-line, fast-acting and non-specific defense towards 
pathogens. It comprises of tissue mechanisms, such as the epithelial surfaces and mucus 
layers, antimicrobial proteins such as lysozyme or defensins, cytokine releasing and tissue 
modifying proteases, the complement and the coagulation systems. Endothelial and 
epithelial cells are also involved in pathogen recognition and defense, as well as the 
sequential signaling events. Additionally, highly specialized immune effector cells carry 
out several important functions. These include NK cells and innate lymphoid cells as well 
as cells of the myeloid lineage: granulocytes (neutrophils, basophils, eosinophils and 
MAST cells), monocytes, macrophages and dendritic cells. The function of the cells 
includes phagocytosis of both pathogens and damaged host tissue, releasing of reactive 
oxygen species and enzymes acting on either the pathogen or host-tissues and second 
messengers such as cytokines and chemokines.  
The innate immune response is not specific to a single antigen epitope, as in the case of 
adaptive immunity. However, there is some categorization of the classes of pathogens 
recognized and in the functions of differentiated cells. Innate cells differentiate and adopt 
a phenotype according to the surrounding immune signals. Especially monocytes and 
macrophages can function in both a pro- and anti-inflammatory manner. Immune cells 
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are classified according to the level of expression of cell surface molecules. These include 
cluster of differentiation molecules (CD), which include pattern recognition receptors 
such as TLRs or antibody recognizing FcRs. (Aristizábal and González, 2013) 
During the first hours and days of acute inflammation, neutrophils are the most abundant 
cells. Local expression of chemotactic and cell-adhesion molecules recruits increasing 
amounts of other immune cells, such as monocytes and T cells. Monocytes are short-lived 
circulating innate immune cells which carry out inflammatory responses after recognizing 
a broad range of antigens by secreting reactive oxygen species, phagocytosis and 
secretion of immune related signaling proteins. The monocyte/macrophage lineage cells 
also play an important role in the interplay of the immune response, by participating in 
the differentiation of adaptive immune cells by cytokine and chemokine contribution to 
the immune environment.  
Monocytes in human and most other animals can be roughly divided into three subsets 
by the expression levels of lipopolysaccharide (LPS) coreceptor CD14 and FcγIII 
receptor, also known as CD16. CD14hi have been referred to as classical monocytes and 
CD16hi as non-classical. The CD14+/CD16+ population is seen as an intermediate in 
differentiation from the classical to non-classical maturation. In mice the classical 
monocyte population express high levels of lymphocyte antigen (Ly)6, and the 
chemotaxis to the gut is C-C chemokine receptor type 2 (CCR2) dependent in both mouse 
and human (Ziegler-Heitbrock, 2014). Non-classical CD16hi monocytes have been 
suggested to patrol endothelia and have no or only limited ability to extravasate (Auffray 
et al., 2007). In the classical monocyte population, there are precursors of some 
macrophages and dendritic cells which, when differentiated, serve as migratory antigen 
presenting cells (APCs).  
However, not all macrophages are differentiated peripheral monocytes from the adult 
bone marrow. Most tissue-resident, like microglia, Langerhans and Kupfer cells have 
migrated to the tissues already at embryonic and fetal developmental stages (Kleer et al., 
2014) and might renew independently, as differentiated cells  (Sieweke and Allen, 2013).  
Macrophages can function in both a pro- and anti-inflammatory manner. Differentiation 
is orchestrated by immune related molecules and signals from the stroma (Desalegn and 
Pabst, 2019). The outdated view of macrophage activation, with classical, IFNγ activated 
M1 and alternative IL-4 activated M2 phenotype extremes is now replaced by a spectrum, 
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within which macrophages can have intermediate traits depending on the tissue location 
and signals received (Murray et al., 2014).  
Anti-inflammatory activation of macrophages is crucial for homeostasis, but also for 
wound healing and the remodeling of tissue. Resolution of inflammation is a complex 
tissue microenvironment-orchestrated feedback loop leading to cessation of 
proinflammatory processes. An appropriate inflammatory response results in the 
activation of anti-inflammatory processes, in which macrophages can participate either in 
an active or in a passive manner. Passive regulation by macrophages support the epithelia 
and ECM production, while the active regulation includes secretion of anti-inflammatory 
lipids and chemokine cleaving proteases, thus inhibiting further neutrophil and monocyte 
recruitment. Resolution associated macrophages switch to anaerobic glycolysis, resulting 
in lactate secretion, which also is an anti-inflammatory signal.  Anti-inflammatory 
macrophages can be identified by increased expression of for instance IL-10, TGFβ 
(Watanabe et al., 2019), mannose receptor (MRC-1) (Gan et al., 2018) and arginine 
metabolizing enzyme ARG1. However, ARG1 is involved in NO production and can be 
induced at lower levels also in the proinflammatory response (El Kasmi et al., 2008). As 
in all physiological and pathophysiological processes, a plethora of cell and molecule 
mediators can be associated to each process.  
1.7.1. Intestinal population of monocyte/macrophage lineage cells 
Even in steady state, most of the mouse adult skin and intestinal macrophages are 
monocyte derived, CCR2-dependent, locally differentiating and influenced by the 
microbiota (Bain, Calum C. et al., 2014). The macrophages are thought to remain in the 
tissue where they have differentiated but may transfer antigens to the dendritic cells which 
in turn migrate to activate adaptive immune cells in the lymph node (Mazzini et al., 2014). 
Several surface markers can be used to identify macrophage subsets, but a lot of overlap 
is seen and often an expression level approach is useful. In the steady state human 
intestine CD14hi monocytes differentiate to CD14lo MHCIIhi macrophages, while in 
inflammatory conditions CD14hiCD11chi cells are suggested to accumulate, as was seen 
in a set of intestinal resection samples from IBD patients (Bain, C. C. et al., 2013). 
Intestinal macrophages divide into different populations which localize to the lamina 
propria, submucosa and muscularis. In the muscularis, microbiota-influenced 
macrophages communicate with enteric neurons and issue a role in peristalsis (Muller et 
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al., 2014). Fetal-derived macrophages reside also in the intestine, and are important actors 
promoting tolerance through IL-10 (Lavin et al., 2015). 
 In mice the CX3C chemokine receptor 1 (CX3CR1) surface expression levels have been 
seen to relate to the responsiveness and function of macrophages. Ly6hi monocytes 
differentiate to CX3CR1hi Ly6lo lamina propria-resident macrophages, which are 
hyporesponsive to TLR stimulation but nevertheless highly phagocytic and clear 
apoptotic or senescent epithelial cells as well as any breaching microbiota. These steady-
state CX3CR1hi cells secrete prostaglandin E2 which maintains the epithelial progenitors  
and play a part in intestinal tolerance by inducing the expansion of activated Treg cells in 
the mucosa through the secretion of IL10, while also constitutively secreting 
physiological levels of TNFα  (Bain, Calum C. and Schridde, 2018).  
It is suggested that differentiation into CX3CR1hi macrophages is disturbed in mouse 
colitis: Triggering receptor 1 (TREM-1) signaling in TLR responsive CX3CR1int 
macrophages decrease secretion of IL-10 and increase secretion of pro-inflammatory IL-
6, IL-12, TNFα (Weber et al., 2011), IL-23, VEGFa, and iNOS (Zigmond, Ehud et al., 
2012). In inflammation, CCR2-dependent recruitment is upregulated (Desalegn and 
Pabst, 2019). The intestinal macrophages have the ability to induce T helper (Th) 17 cells 
and innate lymphoid cells 3 (ILC3) (Bain and Schridde, 2018).  
1.8.Inflammatory bowel disease 
Inflammatory bowel diseases, mainly Crohn´s disease (CD) and ulcerative colitis (UC), 
are states of mucosal inflammation residing in the small or large intestine, respectively. 
The highest incidence is reported in North America, UK and northern Europe, while in 
southern Europe and Asia the incidence is rising. The global age-standardized prevalence 
is 84.3/100 000 with 6.8 million overall cases in 2017. The highest age-standardized 
prevalence, in the higher socioeconomic population of North America, is 422/100 000  
(GBD 2017 Inflammatory Bowel, Disease Collaborators, 2020).  
The etiology of intestinal inflammatory disease is not entirely elucidated. It is thought to 
be in part genetic and in part environmental. For instance, CD is associated with NOD2 
loss-of-function variants, leading to dysfunction in microbial sensing. Other 
polymorphisms found in CD patients involve the autophagy and unfolded protein 
response as well as antimicrobial peptide response. The genetic component of CD is 50%, 
21 
 
while in UC it is thought to be lesser with only 20% genetic impact and a greater 
environmental role. IBD pathophysiology involves dysfunctional immune processes and 
loss of epithelial integrity, with some overlap in the CD and UC inflammatory processes, 
but also distinct features and differences of the localization of the lesions. Whereas CD 
lesions are patched and can reach through the intestinal wall, the UC lesions often affect 
the inner lining of the rectum and distal colon continuously. The symptoms include 
diarrhea and abdominal pain, sometimes bloody stools as well as weight loss and fatigue.  
IBD treatment includes oral short-term and long-term immunosuppressive medications, 
which aim to induce and maintain remission (table 4). 
 
 
The pharmaceuticals can be used in different combinations, if the previous treatment has 
lost efficacy or if the patient does not respond. Also, probiotic products may help, and 
sometimes CD can be treated using antibiotics. Interestingly, but not unexpectedly, there 
is a female predominance of hypersensitivity reactions induced by monoclonal TNFα 
inhibiting antibodies (Zelinkova et al., 2012). Future treatment options could include 
targeting leukocyte trafficking, IL-12, IL-23 or inhibiting cytokine production by 
antisense oligonucleotides  (Wilhelm and Love, 2017). 
1.8.1. Innate immunity and intestinal inflammation 
The macrophages and dendritic cells contribute to intestinal inflammation and are 
suggested play a role in the pathogenesis of IBD. Antigen presenting cell secreted IL-12 
is involved in Th1 induction and macrophage secreted TNFα plays a part in the 
Table 4. Current pharmacological treatment of IBD.  
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proinflammatory crosstalk with Th1 cells. Adding to the vicious cycle of inflammation, 
TNFα induces monocytes to secrete IL-6 and IL-1β. These proinflammatory cytokines 
have been identified to partake in increased Th17 differentiation (Zheng et al., 2014). 
Th17 cells are implicated to be involved in IBD pathophysiology (Gálvez, 2014) and IL-
17 is also increased in patient samples of inflamed gut tissue (Fujino et al., 2003).  
IL-6 combined with TGF-β induces Th17 secretion of IL-21 and IL-23 as a positive 
feedback loop (Zhou et al., 2007) and IL-17 which indirectly induces neutrophil 
infiltration, inflicting tissue damage (Pelletier et al., 2010) and augment further monocyte 
recruitment (Prame Kumar et al., 2018). TNFα and IL-21 induce tissue protease secretion, 
which further exacerbates the forming of intestinal lesions and induce anoikis in 
enterocytes (Geremia et al., 2014). Notably, ablation of Ly6hi monocytes alleviate 
intestinal inflammation in mice (Zigmond et al., 2012). 




TGF-β is produced by several cell types, including immune cells, stromal cells and 
enterocytes  (Jiang et al., 2016). It has a dual role in intestinal inflammation, as it is 
involved in Th17 cytokine induction, but it also has an important function in sensitizing 
T cells to regulatory signaling (Fahlén et al., 2005). Smad7, a protein which inhibits TGF 
signaling has been observed to be upregulated in inflamed intestinal samples from 
Crohn´s patients, while the inhibition of Smad7 restored TGF-β1 - Smad3 signaling and 
downregulation of the inflammation (Monteleone et al., 2001). Stimulated upregulation 
Figure 3. The normal and inflammatory function of lamina propria macrophages, simplified. A. In a 
normal situation, CX3CR1hi macrophages sample luminal antigens and promote tolerance through, for 
instance IL-10 secretion. IL-10 induces T helper cells to differentiate to regulatory T cells. B. Immune 
activation disturb macrophage differentiation and creates proinflammatory signaling and leukocyte influx, 




of TGFβ has been observed in isolated lamina propria macrophages of UC patients, but 
not in those of CD patients (Del Zotto et al., 2003).  
1.8.2. Hormonal impact in the intestine and in IBD 
Estradiol might have a direct effect on intestinal permeability and have been reported to 
rescue the expression of mucin 2 gene (MUC2) and tight junction related genes sequential 
to induced colitis induced downregulation (Song et al., 2018). Loss of estrogen receptor 
signaling is also reported to influence epithelial stem cells and promote crypt expansion 
via TGFβ, Wnt and Ihh mediated stromal crosstalk in transgenic mice  (Hasson et al., 
2014). Other studies have proposed an ERβ specific mechanism for tight junction 
upregulation in the colon (Braniste et al., 2009) as well as for inhibiting shedding of the 
epithelial cells (Wada-Hiraike et al., 2006). 
Straub (2007) discussed an environmental influence on estrogen modulatory abilities and 
proposed that inflammatory context stromal cells induces proinflammatory signaling in 
macrophages. ERβ is expressed in the epithelium (Rudolph et al., 2012) and GPER in the 
epithelial as well as smooth muscle cells (Jacenik et al., 2019). Low amounts of 
cytoplasmic PGR are found in the adult male and female colon, more precisely in the 
epithelial cells of the crypts  (Asavasupreechar et al., 2020). The rapid acting progesterone 
membrane receptors have been found in neuroendocrine tissues, as well as in both cell 
line and primary murine macrophages   (Dressing, Gwen E. et al., 2011). 
Epidemiological studies of Western populations have showed higher prevalence of CD in 
females and UC in males, but with a female predominance in some specific forms of UC 
and an observation of a divergent pattern in Asian populations, where both IBD forms 
seem to be more common in males (Goodman et al., 2020). Ovarian hormone influenced 
changes in disease status have been reported in IBD patients and IBD can sometimes 
influence ovarian hormone regulated processes. For instance, premenstrual and menstrual 
(i.e. low estrogen status) exacerbation of CD symptoms has been reported, but also 
menstrual abnormalities (Bharadwaj et al., 2015) and infertility in CD, but not UC 
patients.  
Interestingly, flares are increased in pregnancies conceived during a period of aggravated 
disease, but not in those conceived at remission, although the sequential cessation of 
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medication can produce some of the flaring. High estrogen status induced by 
endometriosis or oral contraceptives, but not hormone replacement therapy has been 
associated with increased IBD risk in susceptible individuals (Goodman et al., 2020).  
1.9. Hormone receptor mediated signaling and inflammatory response 
ERs have previously been reported to be expressed in several kinds of immune cells, both 
adaptive and innate (Khan and Ansar Ahmed, 2016). Some variation between cell type 
and species have been observed (Kovats, 2015). The nature of both the immune system 
and of the ER and PGR signaling is incredibly complex. Both processes are strongly 
influenced by the environment and by the age and health of the individual. Additionally, 
the ovarian hormone induced effects are tissue specific. Coming together, experimental 
results of ovarian hormone modulatory effect on the immune response are to a great extent 
contradictory. 
1.9.1. Estrogen receptor signaling and inflammation 
In THP1, the leukemic monocyte cell line originating from a 3-year old child, expression 
of ERα36, ERα66, ERβ and GPER1 have been reported (Pelekanou et al., 2016). 
According to our previous research, both ERα and ERβ mRNA is found in THP1 and 
human male CD14+ monocytes ex vivo. Further, the expression of GPER was 
substantially higher in THP1 than in CD14+ monocytes, while ERα was predominant in 
the CD14+ cells disregarding activation status (Polari et al., 2018). 
Both full length ERα66 and AF-1 truncated ERα46 expression have been observed in 
human female CD14+ monocytes and macrophages, along with a macrophage 
differentiation associated increase in ERα46 simultaneously with a decrease in ERβ 
expression. Macrophages, but not monocytes, responded to E2 stimulation by 
upregulating ERα expression through promotor F activity (Murphy et al., 2009). 
However, in a more recent study the ERα36 isoform as well as GPER1 are suggested to 
be the only ERs expressed in human monocytes of both adult males and females, and that 
the previous findings of ERα66 and ERα46 expression would be accounted to differences 
in cell populations, antibody cross-reactivity and translatory issues (Pelekanou et al., 
2016). The expression was observed to be stable throughout the menstrual cycle and 
monocyte differentiation.  
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A significant number of survival-, immune- and metabolic process related genes, as well 
as genes related to stress response and protein folding was differentially expressed after 




There are varied gender differences in the pro- and anti-inflammatory response pattern of 
human monocytes and macrophages. A large meta-analysis of the ex vivo monocyte 
inflammatory response from 15 study populations, conducted by Beenakker et al (2020), 
showed a higher monocyte count in men and a slight increase in LPS stimulated IL-10 
per ex vivo monocyte from adult females, independent of age, health status and 
geographical location. The study also presented slight but persistently elevated TNFα, IL-
1β, IL-6 and IL-12 in stimulated male monocytes compared to increased GM-CSF and 
IFNγ levels in female monocytes, although  the difference diminished after normalization 
to cell counts (Beenakker et al., 2020).  
Hormonal changes in menstrual cycle are associated with increased monocyte secretion 
of IL‐1β, IL‐6 and TNFα in healthy females, most pronounced during menstruation but 
already seen in the luteal phase of the ovulatory cycle (Willis et al., 2003). Cycle phases 
and associated hormone levels described in figure 5 (Hong and Choi, 2018). An increase 
in serum E2 was found to associate with increased neutrophil and monocyte count in 
subfertile women in treatment to induce ovulation. With the increase in numbers, a 
decrease in proinflammatory as well as an increase in anti-inflammatory surface markers 
was observed  (Habib et al., 2018). In female PBMC derived macrophages TNFα, IL-1β 
Figure 4. Differentially expressed genes after short E2 treatment of murine peritoneal monocytes in 
metestrus phase. E2 regulated transcription during 24h shows differentially regulated genes related to the 
immune response, metabolism and cell survival, as well as stress response and protein folding. Image from 
Pepe et al (2017). 
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and IL-10 intracellular levels were reported to decrease by E2 modulation of LPS 
response. Further, markers of alternative activation in menopausal female PBMC derived 
macrophages ex vivo were found to decrease after IL-4/IL-13 stimulation in comparison 
with those from premenopausal females, while IFNγ/LPS treated macrophage responses 
were comparable (Toniolo et al., 2015).  
  
Without the impact of the surrounding tissue, i.e. in in vitro or ex vivo experiments, 
monocytes transiently treated with ovarian hormones often respond in an anti-
inflammatory manner. Estradiol (100nM, 24 h) lowered both IL-6 and TNFα expression 
after LPS stimulation (110 ng/ml, 3 h) in human ex vivo CD14+ monocytes, while 
fulvestrant inhibited the E2 effect (Pelekanou et al., 2016). In another experiment, E2 
(100 nM, 24 h) modulated LPS (10 ng/ml, 12 h) response and inhibited IL-8 secretion to 
media after 72 h, with a paralleled ERα46 increase  (Murphy et al., 2009). In RAW 264.7 
murine macrophage cell line ERα activation have been suggested to amplify the IL-4 
induced resolution of the inflammatory response through regulation of STAT3 and 
SOCS3 pathways, leading to increased Arg1 and Il10 expression (Villa et al., 2015). E2 
also prevented LPS induced morphologic changes associated to activation in RAW 264.7 
macrophages (Vegeto et al., 2004). In a review on estrogen effects on immune processes, 
low level E2 was concluded to induce an increase in IL-1β secretion of 
monocyte/macrophage lineage cells, while high E2 inhibited it  (Straub, 2007). 
Figure 5. Cycle hormone 
concentrations in blood. The relative 
estrogen (red line) and progesterone 
(dashed line) concentrations in blood 
during A. estrus cycle of female mice and 
B. menstrual cycle of human females. The 
concentration of estrogen increases before 
ovulation after which progesterone 
concentration in turn increases. Picture 
from Hong et al (2018).  
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1.9.2. Rodent studies of ERα modulated inflammation 
Animal studies on modulating inflammation via ERα signaling are very varied in setting 
and display an unfortunately broad range of results. The complex nature of both the 
immune system as well as ER signaling and regulation, together with species specific 
differences, may also contribute to some of the variation. Except the E2 dose, length of 
administration may affect the results. In some cases, E2 seems to have an ability to 
aggravate innate inflammation, but it does not cause inflammation in healthy tissue. ERα 
signaling might be stronger associated with aggravated colitis.  
A modest decrease of IL-1β and iNOS mRNA induced by short-time E2 treatment, while 
long-term administration led to proinflammatory response in ex vivo stimulated peritoneal 
macrophages collected without eliciting. The authors suggested that the seemingly 
contradicting, beneficial effects of higher long-term estrogen concentrations seen in MS 
and experimental autoimmune encephalomyelitis were related to surrounding tissue 
responding to E2 in an anti-inflammatory manner (Calippe et al., 2008).  
Lambert et al (2004) had previously reported that the TGC-elicited peritoneal 
macrophages of ERα deficient mice secreted higher amounts of TNFα and that E2 had no 
effect on TNFα secretion. Similarly, bone marrow derived macrophages had not exhibited 
any differences, neither had ERβ deficient peritoneal macrophages (Lambert et al., 2004). 
A  more recent study by Pepe et al (2017) added to the evidence of short-term, endogenous 
surge-mimicking E2 immunomodulatory effects in ex vivo murine bone-marrow and 
peritoneal macrophages. This was observed also in vivo after repeated E2 5 μg/kg s.c. 
injections during 36 or 60h. Both the in and ex vivo models exhibited an increase in anti-
inflammatory markers, such as Arg1 (Pepe et al., 2017).  
In later research, Calippe et al (2010) combined in vivo treatment using estrus or early 
pregnancy levels of estrogen in ovariectomized mice with ex vivo LPS stimulation of 
thioglycolate (TGC)-elicited peritoneal macrophages and reported inflammatory effects. 
E2 decreased PI3K-Akt mediated inhibition of Toll-like receptor (TLR) 4 downstream 
signaling, which increased induced nitrogen oxide synthase (iNOS) and proinflammatory 
cytokines IL-1β, IL-6 and TNFα. The same proinflammatory cytokines were 
downregulated in OVX animals without E2 treatment when compared to intact animal 
cells ex vivo, at both basal and LPS stimulated conditions. Further results from mice with 
a conditional ERα knockout (KO) were presented, confirming that the effect was indeed 
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ERα mediated. The authors speculated that the inflammatory effect of ERα was due to 
chronic administration and referred to their earlier research where only one dose of E2 
was used, leading to an anti-inflammatory result. They did not offer any extensive 
discussion on the inflammatory context here, although eliciting macrophages with TGC 
causes sterile peritonitis. However, in this model, E2 treatment reduced the number of 
elicited macrophages (Calippe et al., 2010).  
In in vivo experiments conducted in inflammatory disease models, researchers have 
reported that the disease activity as well as proinflammatory signaling can be both 
exaggerated or alleviated by estradiol or ERα activation. In intact female mice, induced 
disease models of adaptive and innate mediated colitis were observed to respond 
differently to E2. Th1 driven dinitrobenzene sulfonic acid induced colitis was alleviated, 
but not abolished, by supraphysiological estrogen administration, while in dextran 
sulphate sodium (DSS)-induced colitis which induces an innate response, E2 was seen to 
aggravate tissue destruction and increase TNFα secretion both in M-CSF ablated and in 
wildtype mice. This introduced the question whether the effect was macrophage mediated 
at all. However, monocytes and tissue resident macrophages should still be present in the 
colon of M-CSF-KO mice. The effects of E2 were eliminated by simultaneous 
administration of tamoxifen. In mice without induced intestinal inflammation, E2 did not 
cause any inflammatory changes. Based on the results, the author suggested a genetic 
component in the varied hormonal response of IBD patients, involving for instance E2 
sensitization to bacterial products (Verdú et al., 2002).  
Another Th1-driven colitis model exhibited alleviated disease in E2 treated OVX mice 
after a 90-day release of supraphysiological levels. However, specific ERα agonist treated 
OVX mice exhibited slightly aggravated disease after ERα stimulation, while ERβ 
stimulated group had less animals with severe disease. Intact, untreated ERα-KO mice 
had a lower incidence of severe disease, while ERβ-KO mice did not differ from control 
animals. Further ER-KO/adoptive transfer-experiments indicated ERα deficiency in non-
CD4+ cells was responsible for aggravated disease (Cook et al., 2014).  
Administering a lower, but still supra-physiological dose of E2 to OVX animals and a 
reduced DSS-challenge had a beneficial effect on histological markers of inflammation 
as well as disease activity. This was seen in both intact and OVX E2 treated female mice 
while male mice were more susceptible to inflammation. The mice were allowed to 
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recover before sacrifice, and female mice showed improved recovery measured by 
regaining of body weight (Bábíčková et al., 2015). induced colitis, which resemble CD 
by histopathological features, was observed to be exacerbated if first administered during 
the luteal phase, compared to follicular phase in rats. In the same set of experiments, a 
DSS-induced colitis model in OVX rats E2, but not progesterone, produced suppression 
of inflammatory infiltration and downregulation of proinflammatory macrophage 
inhibitory factor (MIF),  myeloperoxidase and IL-1β. Anti-MIF treatment sequentially 
decreased TNFα (Houdeau et al., 2007). The previously described studies administered 
E2 as a subcutaneous pellet enabling constant release for an extended time. 
An HLA-B27 transgenic rat model has shown beneficial effects of E2 (10 μg/kg) on 
MAST cell and neutrophil inflammatory markers as well as histological and disease 
activity features, using only 5 days p.o. administration. Simultaneous administration of 
fulvestrant reversed the effect, which the authors interpreted as indication of an ERα 
specific activity (Harnish et al., 2004). 
1.9.3. SERM effect on inflammation 
SERMs have been suggested to modulate inflammatory response of several types of 
immune cells. For instance, RAL and tamoxifen affected murine dendritic cells, altering 
the antigen presenting cells towards a less inflammatory phenotype (Nalbandian et al., 
2005). In another study, SERMs induced an anti-inflammatory effect on rat microglia 
(Smith et al., 2011). RAL has been reported to dose-dependently induce the anti-
inflammatory enzyme hemeoxygenase-1, through an ER independent mechanism in 
RAW264.7 cells. Hemeoxygenase-1 product CO is suggested to inhibit iNOS. RAL was 
seen to directly increase xanthine oxidase activity, which was associated to an increase in 
intracellular ROS. ROS increase induced phosphorylation of p38 and CREB, resulting in 
hemeoxygenase-1 expression (Lee et al., 2011).  
In our previously published work, SERM2 and RAL downregulated the TNFα induced 
activity of NF-κB in THP1 cells but upregulated the LPS induced response in contrast to 
E2. E2 had a similar effect on both LPS and TNFα stimulated cells. SERM2 increased 
surface marker expression of MRC-1 and CD163 scavenger receptor in a CD14+ human 
male ex vivo monocyte population differentiated by IFNγ and activated by LPS. 
Significant changes in cytokine expression were not found, except for a slight increasing 
effect on IL-10 by E2, SERM2 and RAL. However, SERM2 and RAL reduced the 
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proliferation rate of T cells in co-culture with donor matched IFNγ and LPS stimulated 
CD14+ monocytes  (Polari et al., 2018).  
In another study by Polari et al (2019) SERM2 alleviated DSS induced colitis in male 
mice, measured by histological analysis of erosion, edema, crypt loss and 
hyperproliferation as well as the staining of anti-inflammatory Mrc-1+ 
monocyte/macrophages matched to observed disease activity scoring. Il10 expression 
was seen to increase in the colon of SERM2 treated healthy mice, but interestingly not in 
those with induced colitis (Polari et al., 2019) possibly reflecting the environment effect 
of ovarian hormones on immune processes. However, the precise molecular mechanisms 
of SERM2 colitis alleviating effect is still unclear, and this thesis project is carried out in 
hope to further illuminate the role of ERα and PGR. Polari speculates, based on increased 
Pgr expression after exposure to SERM2, that the novel compound would function as an 
ERα agonist in this experiment but also addresses the possibility of PGR activation.  
RAL (p.o., 5 mg/kg) has been indicated to alleviate inflammation in DSS-induced colitis 
using female Balb/c mice, measured by disease activity, histological features and serum 
IL-6 and TNFα. Styrene maleic acid encapsulated micellar RAL was observed to further 
improve the effect, due to increased bioavailability of the lipophilic drug. The author also 
suggested the limited distribution of the micellar drug could be used as a means to limit 
adverse effects (Greish et al., 2017). 
1.9.4. Progesterone receptor signaling and inflammation 
As with estrogens, the immunomodulating effect of progesterone is not well understood. 
As there are many factors which influence effects, the results in the literature presented 
here are in part contradictory. It is clear, however, that both innate and adaptive immune 
cells respond to progesterone receptor signaling and immunological processes play a part 
in pregnancy. Monocyte inflammatory responses ex vivo have been reported to increase 
in the first trimester and then to decrease compared to non-pregnant females and was 
associated to higher hCG levels (Ziegler et al., 2018). Progesterone binds to the 
glucocorticoid receptor and can exert some anti-inflammatory effect through that pathway 
(Attardi et al., 2007). Levonorgestrel (LVN), used in the experiments here is PGR specific 
and has greater affinity to PGR than progesterone (Sitruk-Ware, 2006). 
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In mice, progesterone reduced matrix-metalloproteinase 9 (MMP-9) in cervical 
neutrophils and monocytes as well as decreased systemic IL-1β (Furcron et al., 2015). 
MMP-9 is increased in the inflamed tissue of IBD patients and animal models of colitis, 
and it induces intestinal permeability through tight junction loss (Al-Sadi et al., 2019) and 
can facilitate the release of TNFα (Yabluchanskiy et al., 2013). Besides the direct effects 
on immune cells, progesterone signaling to surrounding cells can influence inflammatory 
status. Specific knockout of osteoprogenitor PGR aggravated synovial inflammation in 
both male and female mice (Liu, L. et al., 2020). Progesterone decreased LPS stimulated 
NO production and arginase along with Mrc1 and Il23 mRNA expression activity induced 
murine bone marrow derived macrophages (Menzies et al., 2011).  
Progesterone has been attributed anti-inflammatory effects, but also proinflammatory 
features, possibly depending on the type of signaling. PGR A to B signaling ratio may 
upregulate proinflammatory proteins, such as cyclooxygenase (COX) 2 and NF-κB in 
labor (Shah et al., 2019).  Progesterone has been reported to increase survival and 
augment clearance of intestinal parasite infection in mice (Escobedo et al., 2011). In OVX 
rats progesterone increased inflammation induced by trinitrobenzene sulfonic acid, 
measured by myeloperoxidase activity (Houdeau et al., 2007). In human U937 monocyte 
cell line progesterone treatment was observed to moderately decrease IL-6, while it 
clearly increased TNFα secretion (Jain et al., 2004). 
1.10.  Integration of the hormone induced inflammation modulating 
pathways 
Already established therapeutics of IBD, such as glucocorticoids, anti-TNFα recombinant 
proteins and aminosalicylates, function at least partially by downregulation of NF-κB 
activity. This chapter presents the NF-κB inhibitory potential of ovarian hormone receptor 
mediated signaling. Crosstalk between ER and NF-κB was been reported by Boyce et al 
already in the 1990´s, when the loss of estrogen mediated NF-κB inhibition in osteoclasts 
was presented to play a part in the menopausal exacerbation of bone resorption, via the 
secretion of IL-6 (Boyce et al., 1999).  
NF-κB is a widely expressed protein complex involved in the development and support 
of especially immune cells, but its activation induces proinflammatory response also in 
for instance epithelial cells. Persistent activity of these regulatory proteins is linked to 
many diseases, including inflammatory and autoimmune conditions as well as cancer. 
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The NF-κB response can be initiated through several pathways, such as pathogen-
associated molecular pattern activated TLR through MyD88 signaling or through 
different cytokine receptors, such as TNFR and as such collects the signals from various 
different immunogenic pathways. The κB sites regulate the expression of chemokines, 
adhesion molecules and various cytokines such as IL-1β, TNFα and IL-6. NF-κB also 
orchestrates the expression of genes with products contributing to proliferation and cell 
survival (Kalaitzidis and Gilmore, 2005). NF-κB activation is described in figure 6. 
The inhibitory effect of ovarian hormones on NF-κB can be executed both in the 
cytoplasm and the nucleus. It is feasible, that the interactions vary between cell types and 
tissues. The reported cytoplasmic mechanisms include inhibitory κB kinase (IKK) 
downregulation (Lasarte et al., 2013a), inhibitory κB (IκB) upregulation (Xing et al., 
2012) or a microtubular effect (Ghisletti et al., 2005). In the nucleus, ER activation is 
suggested to block DNA binding (Galien and Garcia, 1997a), compete for co-activator 
proteins (Edith et al., 2000), displace coactivators in the proinflammatory transcriptional 
complex (Nettles et al., 2008), downregulate expression of Nemo at estrus levels (10 nM) 
(Lasarte et al., 2013b) and repress the transcription function of bound NF-κB (Galien and 
Garcia, 1997b). The ligand-binding domain, the hinge region (Ray et al., 1997) and the 
DNA-binding domain of ER have been associated with this interaction and in NF-κB the 













In an ex vivo experiment performed with human peripheral monocytes, activated ERα36 
was suggested to interact with RelA after LPS stimulation and inhibit NF-κB induced 
transcription in the nucleus, and GPER1 to coregulate the process via direct interaction 
with the ERα36-RelA complex before nuclear translocation (Pelekanou et al., 2016). In 
human peripheral macrophages estradiol has been proposed to regulate NF-κB activation 
through inhibiting miRNA inhibition of κB-Ras2 in a hormone stripped environment 
(Murphy et al., 2010). Estradiol have been suggested to suppress JNK1/2 induced IKK 
activity and IκB degradation in cardiomyocytes (Vegeto et al., 2004) or to prevent nuclear 
translocation of RelA via ERα-PI3K pathway without modifying IκB degradation in 
TNFα or LPS stimulated RAW 264.7 macrophages and microglia, but not in MCF-7 or 
SK-ER3 cells.  
Figure 6. NF-κB activation upon immunogenic stimuli. NF-κB consists of dimerizing proteins, RelA 
(p65), c-Rel and RelB, p100/p52 and p105/p50 which function as transcription factors. These Rel 
homology domain containing proteins are regulated by IκB family of proteins, which inhibit the DNA-
binding activity of the Rel homology domain. The response can progress through the canonical and non-
canonical pathways involving varied sources of stimulation and different compositions of IKK´s and NF-
κB dimers. In the canonical pathway of activation, a broad range of immunogenic stimuli can activate the 
IκB kinase complex(IKK) including, amongst other proteins,  IKKα, IKKβ and regulatory subunit 
NEMO. This leads to phosphorylation and degradation of binding IκB,  releasing the cytoplasmic NF-κB 
dimers and enables nucleic translocation and binding to genomic κB sites (Kalaitzidis and Gilmore, 




PGR signaling is also suggested to play part in the inhibition of the NF-κB pathway. 
Pregnancy level progesterone treatment (4h) inhibited NF-κB activity and decreased 
iNOS and IL-6 expression in RAW 264.7 macrophages. Additionally, progesterone 
upregulated suppressor of cytokine signaling proteins (Su et al., 2009).  
SERMs tamoxifen, RAL and fulvestrant have been observed to antagonize the effect of 
E2 on nuclear NF-κB translocation in RAW264.7 macrophages (Ghisletti et al., 2005). 
However, inhibition of the PI3K pathway and sequential increase of NF-κB 
transcriptional activity have also been observed, sequential to chronic administration of 
estrogen in vivo in elicited intraperitoneal macrophages, stimulated ex vivo with LPS 
(Calippe et al., 2008). The interaction can also regulate the ER, as observations of NF-κB 
– ERα crosstalk have been made in, for instance, breast cancer (Frasor et al., 2015). In 
non-immune cells, unliganded ERα, along with NF-κB dimers have been suggested to 
function in the TNFα autoinducing transcription complex, and that E2-bound receptor 
would recruit transcriptional repressors, inhibiting TNFα expression (Cvoro et al., 2006).  
1.11. Summary  
In conclusion, inflammatory disease affects an increasing number of people. While there 
are many current forms of treatment, a well-tolerated immune modulatory treatment could 
benefit IBD patients. The hormonal influence on inflammatory disease is probable, but 
the mechanism is unclear because of contradictory results. Most in vitro experiments 
indicate an anti-inflammatory effect of E2 and RAL, while the results of ex vitro and in 
vivo studies are conflicting. Negative NF-κB  crosstalk have by many been suggested to 
mediate the anti-inflammatory effects of receptor signaling in vitro, although 
proinflammatory, positive crosstalk could also be the case. Signals from the surrounding 
tissue as well as intracellular receptor type or coactivator levels are possible determining 
factors when defining the inflammatory capacity of monocytes and macrophages in vivo. 
In this thesis project, monocyte and macrophage inflammatory responses were modelled 
by THP1 NF-κB reporter monocytes and CD14+ primary monocytes in vitro. Monocyte 
cell lines, such as THP1, can be used as an in vitro model for monocyte and macrophage 
function, especially when paralleled by in vivo studies to draw more definite conclusions 
(Chanput et al., 2014). THP1-Lucia stably express a NF-κB-inducible Luc construct and 








Figure 7. The THP1-Lucia NF-κB reporter cell line. The THP1-Lucia cells are stably transfected 
with a Lucia luciferase, INFβ minimal promoter together with several copies of both the c-Rel binding 
site and NF-κB response elements. NF-κB activity induces secretion of luciferase to culture media, 
which is the sampled and provides a quantifiable luminescent signal after the appropriate substrate is 




2.1. No ligand induced cytotoxicity in THP1 cells 
Neither SERM2, LVN or mifepristone (MFP) exhibited cytotoxic effect at 1 nM to 3 µM 





2.2. PGR ligands modulated the NF-κB activity of THP1 cells  
NF-κB activity assay performed using THP1-Lucia reporter cells showed a statistically 
significant reduction of activation in LVN treated cells (P=0.0008), compared to TNFα 
control. SERM2 together with LVN altered NF-κB activation slightly less, but still 
significantly (P=0.0135) (fig 3a). E2, MFP or SERMs SERM2, ICI and RAL did not alter 
NF-κB activation in a statistically significant manner  in this assay. (fig. 9b-c). In this 
system, SERM2 did not function as an agonist at PGR. 
 
Figure 8. No cytotoxic effects of ER and PGR ligands. Viability assay of A. SERM2, B. LVN and C. 
MFP treated cells, exhibiting no toxic effect in TNFα stimulated THP1-Lucia cells (106 cells/ml). 
Viability was analysed using a fluorometric assay and results were normalised to the viability of TNFα 
control.  










2.3. Transfection upregulated receptor levels, but a siRNA silencing effect was 
observed on both mRNA and protein levels  
The siRNA silencing of ERα and PGR was verified by RT-qPCR and Western blots. The 
transfection induced an increase in the mRNA levels of ESR1. Nonetheless, expression 
was decreased compared to negative control siRNA treated cells at 48h after transfection, 
but not after 72h. However, residual receptor mRNA was present in silenced cells at 
similar levels of the untreated cells (fig 10a). Treating cells with PGR siRNA did not alter 
the expression of ESR1 (fig 10b). PGR expression was also upregulated by the 
transfection, seen also in the transfection reagent control (HiP24, fig 10c) and at both 
negative siRNA timepoints. PGR mRNA was downregulated compared to negative 
control cells at both 24h and 48h post-transfection and again, siRNA knockdown rendered 
the mRNA levels to a similar to that of the untreated cells (fig 10c). The protein level 
differences of ERα (fig 10d) and PGR (fig 10e) were depicted by Western blot and 
sequential image-based analysis of bands. Modest differences of ERα (fig 10f) and PGR 
(fig 10g) protein levels could be seen 24h after transfection. The siRNA verification by 
qPCR and WB indicated unexpected effects and these results indicated that the response 
of the transfected cells could not be interpreted as that of a knockdown model. Instead 
Figure 9. LVN induced modulation of NF-κB activity in THP1-Lucia cells. A. LVN downward modulated 
NF-κB activity in THP1 cells (106 cells/ml) after 48h ligand incubation followed by immune activation by 
TNFα, while B. SERM2 and MFP or C. ICI, E2 or RAL did not induce statistically significant changes. NF-
κB activity was measured by reporter-system from culture media and luminescence was related to viability and 
subsequently normalized to TNF control. Analysis of variance was performed using Kruskal-Wallis test 
followed by Dunn´s test for multiple comparisons. 
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only negative siRNA treated, receptor upregulated cells could be compared to receptor 
siRNA treated, especially in the case of ERα. Still, as the results were normalized to the 
negative control siRNA transfected THP1 monocytes it was probable that the data could 
provide some indications on the nature of the ligand induced modulation of the 







2.4 Decreased basal NF-κB activity by ligand modulation of receptor 
upregulated cells 
Measurements indicated statistically significant decrease in basal NF-κB activation 
induced by receptor ligands in the receptor upregulated cells. Without any immunogenic 
activation, both ESR1 and PGR siRNA treated cells exhibited significant elevation in 
baseline NF-κB activity by ligand modulation. In the ESR1 siRNA treated cells SERM2 
Figure 10. RT-qPCR and WB verification of siRNA silencing of ERα and PGR after 24, 48 or 72 hrs. 
Relative expression of A. ESR1 48 and 72 h after ESR1 siRNA treatment, showing an increase of ESR1 mRNA 
levels in negative control siRNA at both 48 and 72 h, compared to untreated THP1 cells B. unchanged ESR1 
relative expression 48 and 72 h after PGR siRNA treatment and C. knockdown of PGR 24 and 48 h after  PGR 
siRNA treatment, with controls for transfection reagent (HiP) and a mock transfection of a scramble siRNA (neg 
ctrl). D. ERα and E. PGR protein Western blots (24h after transfection) with F. quantification of ERα and G. 
PGR bands, showing a silencing effect on receptor protein levels compared to negative siRNA treated cells. All 
lanes contain equal amounts total protein (50 µg). Bands quantified using histogram areal measurements in 




and LVN increased NF-κB activity (P<0.0001 and P=0.0004 respectively). Further, in 
cells with increased receptor capacity SERM2 and E2 treatment differed in response 
(P=0.0049) while in the knockdown cells SERM2 induced more NF-κB activity 
compared to RAL (P=0.0124) (fig 11a), possibly reflecting SERM2 partial agonism at 
ERα and its activity at PGR.  
In the PGR siRNA treated THP1 cells additional baseline elevation of NF-κB activity 
could be seen in SERM2 (P=0.0322), RAL (P=0.0007) and LVN (P=0.0008) treatment. 
Further, the change in activity was greater when compared to control, than in the  ESR1 
siRNA treated cells. SERM2 and RAL response was not identical here either (P=0.0326) 






Then immunogenic stimulation was added to the experiment. The level of NF-κB 
activation of untreated THP1 cells with, or without TNFα stimulation was compared to 
the level of the negative control siRNA treated cells and found to be slightly lower (fig 
12a). The negative siRNA+TNFα treated control is indicated by horizontal line in the 
graphs.  
NF-κB activity was then measured in siRNA treated cells to observe the modulatory 
effects of receptor ligands on TNFα immunogenic stimulus. In the negative siRNA treated 
cells, i.e. cells with increased receptor capacity, a downward trend could be seen by all 
modulatory treatment, compared to negative siRNA TNF control (fig 12b). In the ESR1 
Figure 11. Baseline measurements of NF-κB activation in ESR1 and PGR siRNA treated cells: no 
TNFα stimulation. With 24 h ligand treatment, but without immunogenic stimulation, A. ERα reduced, 
SERM2 or LVN treated cells showed an increase in NF-κB activation compared to receptor upregulated 
negative control, while B. PGR deficiency resulted in a significant increase of NF-κB in SERM2, RAL and 




siRNA treated cells E2, LVN and MFP modulation decreased NF-κB activity 
significantly (P=0.0449, P=0.0012, P=0.0212, respectively) (fig 12c), indicating a pro-
inflammatory effect of upregulated ERα in this system.  
PGR siRNA treatment seemed to induce a trend of increasing NF-κB activation, seen by 
elevated TNFα control activity and which was strengthened by SERM2 treatment (fig 
12d). SERM2 and RAL exerted similar effects both in the negative control siRNA treated 
cells (fig 12b) as in the ESR1 silenced cells (fig 12c). As expected, and providing a hint 
that the silencing effect was sufficient, LVN did not affect the response of the PGR 
silenced cells statistically significantly. Also, SERM2 was not comparable to neither full 
agonists in this system and markedly, but not statistically significantly increased NF-κB 
activity in PGR siRNA treated cells (fig 12d).  






Figure 12. Pooled data of NF-κB activity assays, showing individual experiments and mean. A. 
siRNA treatment slightly increased the response to TNFα stimulation. B. No significant change in 
TNFα induced NF-κB activation in SERM, E2 or LVN treated (24 h), negative control siRNA 
transfected cells, but a downward trend by RAL, E2, LVN and MFP treatment. C. ERα silenced cells 
showing a slight but significant reduction by E2 as well as PGR ligands, but not by SERM treatment. 
D. PGR silenced cells with no statistically significant changes, although an average 50% increase in 
NF-κB activity was seen in SERM2 treated cells. All results were normalized to negative control 
siRNA treated TNFα control (black line). Analysis of variance was performed using Kruskal-Wallis 
test followed by Dunn´s test for multiple comparisons. 
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When the NF-κB activity data from receptor knockdown cells (fig 12) was analyzed for 
ligand induced differences in NF-κB activation no significant effect could be found in the 
ESR1 silenced cells (fig 13a). In the PGR knockdown experiment, however, SERM2 and 
LVN modulated cells responded with elevated NF-κB activation compared to receptor 
increased negative control, when stimulated with TNFα (fig 13b), although only SERM2 





2.5 PGR modulation induces a strong proinflammatory response in a hormone 
depleted environment 
One experiment was conducted using hormone stripped media to distinguish whether 
possibly iFBS originated hormones could interfere with the results of previous 
experiments. In a hormone-depleted environment a trend towards higher NF-κB 
activation was observed by both PGR mediated signaling in the ESR1 siRNA treated cells 
and by PGR transfection induced upregulation. Reduced PGR receptor capacity 
decreased NF-κB activity as in the ESR1 silenced TNFα control and in the LVN treated 
cells. In the ESR1 negative control SERM2 differed from LVN treated cells (P=0.0259), 
but not as much as LVN differed from MFP (P=0.0052) (fig 14a). The luciferase assay 
exhibited the trend clearer (fig 14b), while the fluorescence-based viability assay 
exhibited high variability (fig 14c).  
The PGR silencing experiment exhibits the results in a more consistent manner, and E2 
treatment increased NF-κB activity in receptor upregulated cells (P=0.0056) (fig 14d). 
Figure 13. The pooled NF-κB data analysed by differences in ligand sensitivity. The picture 
represents the same data as depicted in fig 12, but statistical analysis differs. Here, it was conducted by 
by ordinary two-way ANOVA and Tukey´s test for multiple comparisons.  
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SERM2 and LVN differed in NF-κB modulation (P=0.0056). Here, receptor upregulation 
was also seen to increase NF-κB activity in the raw luminescence data (fig 14e), and the 














Figure 14. NF-κB activity of THP1 cells in hormone depleted culture. The DCC depletion of iFBS derived 
hormones from the culture media induced proinflammatory signaling in the receptor increased control cells. 
A. Receptor increased LVN treated cells exhibited significantly higher NF-κB activity compared to SERM2 
or MFP treated cells. B. luciferase measurements were higher in all negative siRNA treated cells compared to 
ESR1 siRNA, but C. variances in viability abolished the effect. D. In PGR siRNA treated cells the 
proinflammatory features of receptor upregulated cells were more evident, seen also in E. luciferase 
measurement and after being normalize to F. viability. THP1-Lucia cells were cultured in a hormone depleted 
media, and similarly assayed for NF-κB activity as in previous experiments, using receptor ligands and TNFα 




2.6 PGR antagonist increased TGFβ, IL1β and IL6 expression in THP1 cells 
The cytokine expression modulating effects of ovarian hormone receptor signaling was 
measured in THP1 cells in order to compare the line cell and primary cell responses and 
to verify the previously presented NF-κB activity modulating model. The measured effect 
of ER and PGR ligands on LPS induced cytokine gene expression in THP1-Lucia cells 
was LPS dependent for MRC1 (fig 15a) and ARG1 (fig 15b) and neither ER nor PGR 
ligands had any effect. IL10 (fig 15c) expression by LVN was similar to vehicle treated 
cells but did not differ significantly from LPS control.  
Both LVN (P=0.0061) and MFP (P=0.0127) treatment produced a significant increase in 
the expression of TGFβ (fig 15d). IL1β expression (fig 15e), however, was upregulated 
by MFP, and likewise downregulated by LVN, hinting at an agonist-antagonist effect of 
PGR which unfortunately was not statistically relevant. IL6 expression (fig 15f) was 
significantly upregulated by MFP (P=0.0215), while LVN did not seem to have a strong 
effect. IFNγ was very weakly expressed, or not expressed at measurable levels (fig 15g). 
SERM2 and RAL effects on LPS induced  THP1 cytokine expression were similar, except 
for IFNγ expression (fig 15g), which was not measurable in the SERM2, but was present 
in RAL treated cells at levels similar to LPS control. LPS stimulation did not affect the 
expression of TLR4 (fig 15h), but possibly a hint of PGR agonist-downregulation and 











2.7 PGR agonist LVN downregulated MRC-1, IL-10, TGFβ as well as IL1β and 
IL6 in hCD14+ monocytes ex vivo 
The ovarian hormone mediated signaling modulatory effect on LPS treated hCD14+ 
monocyte cytokine expression was measured to verify the line cell results and to bridge 
the previously presented results to the upcoming siRNA silenced hCD14+ monocytes 
(sections 2.9 and 2.10) The effect of ER and PGR ligands on the LPS induced cytokine 
expression was modest and mostly reflected the strong proinflammatory stimuli in human 
primary CD14+ monocytes.  
PGR agonist LVN statistically significantly downregulated MRC1 expression (P=0.0493) 
(fig 16a). ARG1 was upregulated by RAL and to a lesser extent E2 (fig 16b). IL10 (fig 
16c) and TGFβ (fig 16d) were both significantly downregulated by LVN (P= 0.0015 and 
P=0.0181, respectively). Proinflammatory cytokine expression was decreased by LVN 
treatment, both IL1β (fig 16e) and IL6 (fig 16f) significantly (P=0.0268 and P=0.0027, 
Figure 15. Receptor ligand effect on the cytokine expression of LPS treated THP1 monocytes. 
The expression of a) MRC1 and b) ARG1 in the ligand and LPS treated cells did not differ from LPS 
control. c) IL10 was downregulated by LVN, but not significantly and d) TGFβ was increased by both 
LVN and MFP. e) IL1β was decreased by LVN, while both IL1β and f) IL6 were increased by MFP. 
THP1-Lucia cells were cultured together with SERM2, raloxifene, PGR agonist or PGR antagonist, 
all at 1 uM concentration for 24 hrs before stimulating with LPS (10 ng/ml) and additional 24 h 
incubation before NF-κB activity was assayed by bioluminescence. Analysis of variance was 
performed using the Kruskal-Wallis non-parametric method and Dunn´s test for multiple comparison. 
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respectively). IFNγ expression was stable in the primary monocytes, but the downward 
trend induced by RAL, E2 and LVN was not statistically significant (fig 16g). The effects 
of SERM2, RAL and E2 on cytokine expression were similar, except for ARG1 of which 
the expression by SERM2 was decreased compared to RAL (fig 16b), and IFNγ of which 







The cytokine expression of THP1 was not identical to that in primary CD14+ monocytes. 
THP1 had a stronger MRC1 response to LPS, with a 10-fold reduction in the expression 
compared to vehicle treated cells (fig 15a). hCD14+ cells responded with a 3-fold 
reduction after LPS treatment (fig 16a). ARG1 seems to be more strongly expressed in 
the line cells with an LPS induced decrease (fig 15b), as LPS treatment of hCD14+ cells 
increased expression of ARG1. Also, the RAL and E2 induced ARG1 response was 
present only in the primary cells (fig 16b). IL10 was stronger induced by LPS in the 
A B C D 
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Figure 16. Receptor ligand effect on the cytokine expression of LPS treated human primary CD14+ 
monocytes. The expression of a) MRC1 was significantly reduced from LPS control by LVN. b) ARG1 
was upregulated by RAL and to a lesser extent E2, but it did not reach significance. c) IL10 mRNA was 
significantly downregulated by LVN as well as d) TGFβ. Expression of e) IL1β and f) IL6 were 
significantly decreased by LVN. IFNγ activated CD14+ monocytes were cultured together with receptor 
ligands, all at 1 uM concentration for 24 h before stimulating with LPS (10 ng/ml) and additional 24 h 
incubation before RNA extraction and RT-qPCR. Analysis of variance measured by Kruskal-Wallis test 




primary cells (fig 16c), and LVN downregulation was comparable, although it did not 
reach statistical significance in THP1 cells.  
The hCD14+ TGFβ expression was more extensively downregulated by LPS (fig 16d), 
and interestingly the ligand induced modulation of LPS response was upregulation in 
THP1 cells (fig 15d), while the trend was opposite in primary cells. However, the 
expression of proinflammatory IL1β and IL6 seemed comparable between the THP1 line 
cells and the adult primary monocytes (fig 15e-f, fig 16e-f), although the LVN response 
was clearer and statistically significant in the mature primary cells. IFNγ was more stably 
expressed in the primary cells with a trend towards downregulation by RAL, E2 and LVN  
(fig 16g), while in IFNγ was not measured in the SERM2 treated THP1 cells at all and 
LVN modulation augmented IFNγ expression (fig 15g), in opposite of the primary cells. 
2.8 ERα upregulation increased proinflammatory cytokine expression in 
hCD14+ monocytes ex vivo 
An ESR1 siRNA silencing experiment was conducted to compare the modulation of LPS 
induced cytokine response by ERα mediated signaling in the receptor upregulated versus 
reduced cells. Downregulation of the receptor could be seen in the vehicle treated, ESR1 
reduced cells, compared to upregulated negative siRNA treated cells. LPS reduced the 
overall expression of the receptor but the knockdown effect was still evident in RAL 
treated cells (P=0.0146) (fig 17a). MRC1 was slightly downregulated in ESR1 silenced, 
vehicle treated cells compared to the NEG counterpart, and an approximately 10-fold 
reductive LPS effect could be observed (fig 17b). ARG1 expression was not influenced 
by the receptor silencing or to any greater extent by LPS (fig 17c). IL10 was significantly 
increased in the NEG+RAL cells, compared to LPS NEG control but otherwise any 
consistent silencing effect could not be seen (fig 17d).  
TGFβ was downregulated in the ESR1 silenced, vehicle treated cells, but the effect was 
indistinguishable after LPS stimulation (fig 17e). The expression of IL1β was increased 
in the receptor upregulated NEG cells, compared to ESR1 silenced counterparts, and LPS 
control as well as RAL treated cells (P=0.0005) (fig 17f) . IL6 was likewise upregulated 
in the NEG cells, with a statistically significant decrease in all groups (LPS P=0.0002, 
SERM2 P<0.0001, RAL P=0.0007), except vehicle treated cells where, without 
immunogenic stimulation IL6 was not expressed (fig 17g). IFNγ mRNA increased 
consistently, although not significantly, in the ESR1 reduced cells (fig 17h).  REL A 
48 
 
expression levels were significantly affected by silencing in the LPS control (P=0.0452) 
as well as RAL (P=0.0057) treated cells, but not in SERM2 or vehicle treated cells (fig 
17i). The expression of MRC1 (fig 17b) and cytokine genes IL1β (fig 17f), IL6 (fig 17g) 
and IFNγ (fig 17h) were consistently different in the silenced cells. Less clear, but still 
detectable difference in ERα (fig 17a), TGFβ (fig 17e) and RELA (fig 17i) expression was 
seen, hinting at an effect of reduced receptor capacity. The cytokine relative expression 
analysis in LPS and ER and PGR ligand treated human primary monocytes was 










Figure 17. Receptor ligand effect on the cytokine expression of LPS treated human primary CD14+ 
monocytes. The expression of A. ESR1 B. MRC1 was strongly reduced by LPS and the expression was 
consistently but not significantly upregulated in the receptor increased cells. Please note the two-part y-
axis. C. ARG1 was not consistently affected by ESR1 silencing. D. IL10 was not consistently affected by 
silencing, while E. TGFβ was significantly downregulated in vehicle control but not after LPS treatment. 
Expression of F. IL1β and G. IL6 mRNA was significantly and consistently downregulated in the silenced 
cells. H. IFNγ was consistently upregulated in the silenced cells. I. REL A was downregulated in the LPS 
control as well as RAL modulated cells. Negative control siRNA treated or ERα silenced, IFNγ activated 
CD14+ monocytes were cultured together with receptor ligands, all at 1 uM concentration for 24 hrs before 
stimulating with LPS (10 ng/ml) and additional 24 h incubation before RNA extraction and RT-qPCR. 
Statistical analysis by ordinary two-way ANOVA followed by Tukey´s test for multiple comparisons. 
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2.9 PGR upregulation increased proinflammatory cytokines in hCD14+ 
monocytes ex vivo 
A similar, but PGR silencing experiment was also performed in the human primary 
monocytes but here the siRNA effect was not fully articulated. In the LPS control samples 
PGR mRNA is present in the NEG cells while no PGR expression could be measured in 
the PGR siRNA treated. However, the effect in vehicle control is opposite, and neither 
SERM2 nor RAL treated cells showed reduced expression in the cells which should have 
reduced receptor capacity (fig 18a). MRC-1 was downregulated by LPS, but a decrease 
could be observed in the PGR silenced cells only in the vehicle control (P<0.0001) (fig 
18b). ARG1 was expressed rather evenly in all cells, except of a marked downregulation 
in the SERM2 treated PGR silenced cells (fig 18c).  
IL-10 was consistently downregulated in the PGR silenced cells compared to NEG 
counterparts, significantly so in the SERM2 modulated LPS response (P=0.0284) (fig 
18d). TGFβ mRNA levels were markedly reduced by LPS compared to vehicle, with only 
a weak hint of downregulation in the PGR reduced cells (fig 18e). IL-1β and IL-6 were 
slightly but consistently downregulated in the PGR reduced cells with a clear LPS effect 
(fig 18f). LPS induced IFNγ expression varied, with a trend towards upregulation in the 
NEG cells except for in the RAL modulated response (fig 18h). REL A was expressed 
evenly, with downregulation in PGR silenced SERM2 treated monocytes , and a 
consistent trend in all the LPS treated cells, while without immunogenic stimuli the PGR 












Cytokine expression of ESR1 or PGR reduced human primary CD14+ monocytes was not 
identical to that of non-transfected CD14+ human primary monocytes. First, regarding 
receptor silencing effect, PGR expression was less affected compared to ESR1, but the 
latter was clearly affected by LPS (fig 17a). MRC1 was upregulated by the ESR1 siRNA 
treatment, with a 10-fold reduction compared to vehicle after LPS treatment (fig 17b) 
while non-transfected as well as PGR silenced CD14+ cells decreased by approximately 
4-fold (fig 16a, fig 18b). Receptor upregulated NEG siRNA treated cells expressed higher 
levels of MRC-1 compared to both ERα and PGR reduced cells (fig 16a, 17b, 18b). ARG1 
Figure 18. Receptor ligand effect on the cytokine expression of LPS treated human primary CD14+ 
monocytes. The expression of A. PGR was unstable with no consistent differences. B. MRC-1 was 
reduced by LPS, and significantly downregulated by PGR in vehicle treated cells. C. no consistent 
differences were observed in ARG1 expression. D. IL10 was consistently downregulated by PGR 
silencing, reaching significance in SERM2 modulated cells. E. Only an LPS effect could be seen on TGFβ 
mRNA. Expression of F. IL1β and G. IL6 were slightly but consistently downregulated by PGR silencing. 
H. IFNγ was downregulated in the silenced LPS control cells as well in SERM2 modulated. I. REL A was 
downregulated in the silenced SERM2 modulated cells. Negative control treated or PGR silenced, IFNγ 
activated CD14+ monocytes were cultured together with receptor ligands, all at 1 uM concentration for 
24 hrs before stimulating with LPS (10 ng/ml) and additional 24 h incubation before RNA extraction and 
RT-qPCR. Analysis of variance by ordinary two-way ANOVA followed by Tukey´s test for multiple 
comparison. 
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expression was increased by RAL and E2, but not SERM2 or LVN modulation of LPS 
response in non-transfected cells (fig 16b), while it was rather evenly expressed in both 
silencing experiments, except for an decrease by SERM2 modulation in PGR silenced 
cells which was not observed in the ERα reduced cells (fig 17c, 18c).  
Statistically significant upregulation of IL10 by RAL was observed in the ERα reduced 
cells (fig 17e), but not in the non-transfected cells (fig 16c). The receptor reduction effect 
was clearer in PGR silenced cells (fig 18d), compared to ERα silencing (fig 17d), possibly 
indicating a role for unliganded PGR in IL10 expression since LVN reduced IL10 in the 
non-transfected cells (fig 16c). The LPS effect on TGFβ expression was increased in the 
ERα reduced cells (fig 17e) compared to PGR reduced (fig 18e) and non-transfected (fig 
16d). RAL did not significantly alter IL1β nor IL6 expression in the non-transfected cells 
but induced a downward trend (fig 16e-f) which was reversed in ERα reduced cells (fig 
17f-g) but not in the PGR reduced cells (fig 18f-g).  
Reducing ERα upregulated IFNγ in disregard of the ligand treatments (fig 17h), while 
reducing PGR downregulated it (fig 18h) compared to receptor upregulated NEG cells. 
SERM2 modulation of IFNγ expression was similar in both non-transfected and ERα 
silenced cells. Downward modulation by RAL was seen in non-transfected cells (fig 16g) 
and PGR silenced cells (fig 18h) while not in the ERα reduced cells (fig 17h). REL A was 
possibly affected by both ERα and PGR reduction.  
SERM2 might have modulated responses via PGR activation, since the decrease was 
significant in PGR silenced cells (fig 18i), but no effect was seen in the ERα (fig 17i) 
silencing experiment. RAL, which in non-transfected cells imitated the response of E2, 
did not induce any change in REL A expression in PGR reduced cells (fig 18i) but in ERα 
reduced the difference was significant. Overall SERM2 and RAL had similar effects on 
the cytokine expression profile of hCD14+ monocytes ex vivo, except differences in 
ARG1 and IFNγ in both non-transfected (fig 16 b and g) and PGR siRNA treated 





According to the results presented here, ERα signaling alone has little immunomodulating 
effect on monocytes. However, upregulation of ERα protein levels results in 
proinflammatory signaling via the activation of NF-κB and increased expression of 
proinflammatory cytokine IL-1β and IL-6. The results also indicate that PGR mediated 
signaling decreases the NF-κB activity of THP1 monocytes and reduces the hCD14+ 
monocyte expression of proinflammatory cytokines IL-1β and IL-6. However, PGR 
signaling also decreased MRC-1, IL-10 and TGFβ, which are thought of as anti-
inflammatory markers. However, upregulation of PGR strongly induces inflammation in 
hormone depleted culture, while without immunogenic stimuli PGR upregulation and 
signaling consistently decreased NF-κB activity. Since receptor silencing leads to an 
increase in the activation of NF-κB even without immunogenic activation, one could 
speculate on a baseline inhibitory effect of PGR signaling.  
3.1 PGR but not ERα signaling modulates inflammation in non-transfected 
THP1 and CD14+ cells 
A greater proportion of the in vitro research conducted on the effects of SERMs, E2 and 
ERα signaling indicates an anti-inflammatory effect, especially in experiments using 
short treatment periods (Ghisletti et al., 2005) (Polari et al., 2018). These kinds of results 
have been reproduced in ex vivo experiments using monocytes or macrophages from E2 
or SERM treated animals  (Pepe et al., 2017)  (Greish et al., 2017). Also, some in vivo 
experiments suggest that estrogen receptor mediated signaling alleviates inflammation 
and decreases disease activity scores in innate colitis (Harnish et al., 2004) (Bábíčková et 
al., 2015).  
However, contradictory results have been published. Long-term administration of E2 to 
OVX mice before eliciting monocytes have induced proinflammatory signaling when 
challenged ex vivo (Calippe et al., 2010).  DSS-induced colitis has also been reported to 
exacerbate during E2 treatment of intact mice (Verdú et al., 2002) (Houdeau et al., 2007). 
Consistently with the flaring of pregnant IBD patients (Goodman et al., 2020), E2 does 
not induce an increase in inflammation in the intestines without an induced inflammatory 
foundation (Verdú et al., 2002).  
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E2 induces a downward trend in THP1 NF-κB activity (fig 9c). Since there are indications 
that the E2 rapid response mediates the anti-inflammatory effects, a shorter ligand 
incubation could have stronger accentuated the immunomodulating features. For 
instance, previously a 10-minute E2 incubation have been successful in inhibiting NF-κB 
translocation in vitro (Ghisletti et al., 2005) and the approximately 22 h activity period 
induced by LPS was shortened to 8 hrs in E2 modulated cells (Villa et al., 2015). This 
indicates a possibility of anti-inflammatory properties in short, but not in longer 
experiments. Besides timing, concentration of E2 may be crucial to the results, as 
miRNA-mediated inhibition of NF-κB, for instance, was seen using higher, 100nM 
concentrations of estradiol (24 h incubation) in hormone stripped media (Murphy et al., 
2010).  
In our setting PGR seems to downward modulate NF-κB activity (figures 9, 11b, 12c, 13) 
and induce an anti-inflammatory cytokine expression pattern. PGR antagonist increases 
IL1β and IL6 in THP1 cells (fig 15) while PGR agonist decreases them in CD14+ 
monocytes (fig 16). A downward modulating effect of PGR signaling on IL-1β have been 
reported in choriodecidual tissue, while IL-6 downregulation has been reported in cell 
line monocytes (Jain et al., 2004).  The cytokine expression experiments reveal 
comparable IL-1β and IL-6 responses in line and primary cells while for instance IFNγ is 
substantially more stably expressed in the primary monocytes. Any upregulating effect 
of ERα signaling on the markers of anti-inflammatory phenotype, as MRC-1 or ARG1, 
could not be observed. However, hCD14+ cells downregulate MRC1, IL10 and TGFβ 
expression sequential to PGR signaling (fig 16). MRC-1 downregulation by progesterone 
treatment have previously been reported in ex vivo IL-4 stimulated macrophages from 
male mice (Menzies et al., 2011). 
Previously, inflammation induced decrease of IL-10 have been reported in vivo or in 
extracted intestinal macrophages  (Bain et al., 2013) (Weber et al., 2011). In our 
experiments, IL10 is upregulated sequential to the pro-inflammatory response, and this is 
seen here especially in the LVN treated CD14+ cells. Less pro-inflammatory activity 
decrease IL10 expression and it consistently follows the level of IL1β and IL6 mRNA (fig 
16). Similar results are reported also in female IFNγ/LPS induced PBMC derived 
macrophages (Toniolo et al., 2015). IL-10 provides negative feedback in inflammation 
(Chang et al., 2007), and in this monocyte monoculture it might be reactive. Anti-
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inflammatory cytokine IL-10 have been associated with intestinal barrier sparing effect 
in DSS-inflamed colon, through increased macrophage oxidative species mediated tissue 
damage in knockout mice (Li et al., 2014) possibly suggesting a higher role in 
macrophage IL-10 response than IL-10 secretion. Although macrophage secretion is 
thought to induce tolerance in the gut, CX3CR1 macrophage-specific IL-10R ablated 
mice developed spontaneous colitis, while inhibition of IL-10 secretion had no effect in 
that model (Zigmond, E. et al., 2014).  
None of the effects could be attributed to changes in TLR4 expression, indicating changes 
in signaling downstream to the receptor. In other research, LPS have been observed to 
induce TLR4 expression in RAW 264.7 cells (Vegeto et al., 2004) but not in the elicited 
murine peritoneal macrophages, stimulated ex vivo (Calippe et al., 2010).  
3.2 Strong transfection effect brought challenges to interpreting ligand effect on 
the inflammatory response  
The human primary monocyte cytokine expression analysis of siRNA treated cells was 
initially designed to enable verification and to provide a tool to examine the compatibility 
of cell line experiments. The strong transfection effect on monocytes definitely brings 
challenge to interpreting results. It is noteworthy, that the transfection actually increases 
the levels of receptor protein and thus the results are interpreted as the effect of receptor 
upregulation (fig 10). As the liposomal transfection reagent induced morphological 
changes, such as membrane blebbing in both cell line and primary monocytes as well as 
increased cell-cell adhesion and decreased viability (data not shown). It is known that 
cells under various stresses upregulate mitogenic and survival enhancing pathways in 
order to escape apoptosis (Portt et al., 2011) and could speculate on the possibility that 
the ERα upregulation could induce anti-apoptotic signaling in the cells.  
Baseline measurements of NF-κB activation in transfected cells indicates an anti-
inflammatory effect by especially PGR upregulation without immunogenic stimuli, as it 
rather consistently reduced the NF-κB response. It is possible, that an apoptotic effect of 
TNFα affected the measurements in the other experiments (Dreschers et al., 2013). As 
the progesterone effect on innate immune cells varies, perhaps one could speculate that 
PGR upregulation would, in a temporary manner, downregulate the inflammatory 
response but by longer exposure upregulate it and thus increase the ability of the 
monocytes or macrophages to clear pathogens. 
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In normal culture conditions, upregulation of ERα can induce a proinflammatory effect 
on NF-κB activity (fig 12b) and an increase in TGFβ, IL-1β and IL-6 mRNA (fig 17 e-g). 
This might be comparable with specific ERα signaling in vivo, which was attributed 
inflammatory features in a Th1-driven colitis model where E2 alleviated the colitis in 
intact animals but ERα specific signaling did not, and a decreased incidence of severe 
disease was observed in ERαKO animals (Cook et al., 2014).  
In the primary hCD14+ monocytes LPS decreased ERα mRNA levels in primary CD14+ 
monocytes. Many research groups have noted pro- or anti-inflammatory effects of 
estradiol and ERα on the response to LPS in different cell types. Downregulation of ERα 
by LPS have been reported in microglia (Smith et al., 2011), endothelial cells (Holm et 
al., 2010) and female PBMCs (Toniolo et al., 2015). Opposite results, i.e. an LPS induced 
increase in ESR1 mRNA levels have also been reported (Vegeto et al., 2004) and ERα at 
protein levels in adherent human PBMCs, with a male predominance in upregulation 
(Campesi et al., 2017). LPS did not exert the same effect on PGR mRNA (fig 18a).  
ERα signaling induced a trend towards downregulating IFNγ in the hCD14+ monocytes 
(fig 16g and 17h), opposed to what have been reported in innate (Siracusa et al., 2008) 
and NK cells  (Gourdy et al., 2005). The IFNγ modulating effect is suggested to be more 
pronounced in females (Kovats, 2015), which might explain why our male primary 
monocytes responded differently. 
3.3 Is SERM2 an agonist or antagonist in this system? 
SERM2 (1µM) treated cells did not decrease NF-κB activity in these experiments, 
interestingly even increasing it in the PGR silenced cells (fig 12d). This could be 
explained by SERM2 partially inhibiting PGR. According to Polari et al (2019), SERM2 
binds 50% efficiently to ERα at below nanomolar, to ERβ at 13 nanomolar and to PGR 
at higher, 210 nanomolar concentrations. The agonist-antagonist effects change at 
different concentration of SERM2. According to Polari et al (2018) SERM2 has 
antagonist properties at lesser, 2-100 nM concentrations in MCF-7 and Ishikawa cancer 
line cells while agonism was observed at higher, 100-1000 nM concentration but only in 
the Ishikawa cells. One could speculate that 1 µM SERM2 functions as a partial agonist 
at ERα in THP1 and CD14+ cells, while its effects are mostly not similar to LVN at PGR 
and the adding of both LVN and SERM2 to THP1-Lucia cells indicated slight antagonism 
(figure 9a). There is no data available on the nature of the SERM2-PGR response.  
56 
 
As the unliganded ERα was seen to participate in the transcription of TNF and receptor 
activation recruited corepressors of the cytokine production (Cvoro et al., 2006), a 
question remains whether ERα upregulation could leave enough unliganded receptor to 
override the inhibition? Another possibility would be the predominance of ERα 
homodimers, as specific ERα mediated signaling induce and increase proinflammatory 
signaling (Cook et al., 2014). Since the response to the same E2 ligand can vary so greatly 
even in vivo, it could indicate that the reason lies in processes below the receptor 
activation. As E2 activation negatively regulates the receptor capacity, this might be a 
possible explanation of high concentration anti-inflammatory effect. One could speculate 
on the possibility whether receptor saturation would have an effect on dimer formation, 
and if so, would it result in increased or decreased ERαβ heterodimers?  
Since the ligand-based, consistent pharmacological modulation of ERα and possibly also 
PGR is difficult, a possibility of allosteric activators or co-agonists (Leitman et al., 2010) 
stabilizing a certain conformation could be an attractive idea. What if it was possible, not 
just to enhance or inhibit the effects of endogenous ovarian hormones, but to find a part 
in the pathway where the endogenous response can be modulated towards or even 
stabilized as a more beneficial one in specific tissues? As the coactivator expression varies 
by cell type and is a defining factor for the receptor signaling, protein-interaction studies 
conducted as close to in vivo conditions as possible, could shed further light on the 
possibilities of ovarian hormone receptor induced immune modulation.  
3.4 Confounding factors 
It is clear, that without the signals from the surrounding tissues as well as other types of 
immune cells, in vitro and ex vivo experiments do not necessarily replicate the animal 
studies. The effects of estrogen on the immune response seem to be highly context and 
dose-time dependent. There are still many open questions regarding this field of research, 
and choosing the relevant models is of utmost importance as the setup has such great 
influence on the results. As the experiments done by different groups are not standardized, 
they are hard to compare, but possibly a meta-analysis of the experiment setups including 
time and concentration of treatment as well as immune stimulation and model could verify 
some patterns which could be anticipated here.  
E2 signaling through other pathways can evidently not be ruled out in these experiments. 
Besides ERα, the remaining estrogen responsive receptors ERβ and GPER could be 
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confounding factors regarding the E2 and SERM induced modulation of inflammatory 
response. GPER promotes rapid anti-inflammatory signaling by estrogen in murine 
macrophages  (Rettew et al., 2010). ERβ is a possible interactor in these experiments but 
investigating this was ruled out from this project. Another thing not considered is ER and 
PGR complexing. Although short silencing experiments are not suitable to investigate 
these effects, full knockout immune cells could be generated to improve the chances of 
gaining reliable results.  
As previously discussed, the immune system is very complex and highly influenced by 
both the environment and the physiological state of the individual. The reports of ER 
mediated direct effects on the immune response, such as cytokine release, are 
contradictory and several other mechanisms need to be considered. ER and PGR have 
important neuroendocrine function  (Dressing et al., 2011) and their signaling can affect 
neuroendocrine immune regulators such as substance P (Sarajari and Oblinger, 2010). 
Another possible direction of research could be tissue inflammatory processes, such as 
prostaglandin signaling (Blesson et al., 2012).  
When using THP1 line cells in experiments, the cancerous origin must be considered. 
Cancer cells might use aberrant signaling pathways and leukemic cells are intrinsically 
immature. The expression profile and function may differ from circulating monocytes in 
vivo, and to even a greater extent from the monocytes homing and differentiating in the 
gut. THP1 cells have been observed to be a good model for monocytes in tuberculosis  
(Madhvi et al., 2019) as well as in atherosclerosis, although validation in either ex or in 
vivo experiments is stressed (Qin, 2012). Still, the THP1 used here were a mixed 
population and thus the response varies to a greater extent compared to extensively 
characterized monocyte populations.  
Circulatory CD14+ monocytes are not macrophages either. Villa et al (2015) measured 
an anti-inflammatory response induced by IL-4 and found an E2 induced increase in Il10 
and Arg1 expression, which was not seen in these results (fig 16), but the experiments 
also differed in angle and set up. However, IL-4 activated macrophages may resemble the 
homeostatic residential CX3CR1hi intestinal macrophages to a greater extent than the 
inflammatory CX3CR1 intermediate (fig 3) and thus monocytes may be an appropriate 
model for the only partly differentiated inflammatory cells recruited to the gut.  
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Other confounding factors can be culture conditions, transfection efficacy and 
inconsistencies in viability after immunogenic stimulation. The notably consistent 
proinflammatory response to PGR upregulation (fig 10) in the hormone depleted negative 
transfected cells seen both in the ESR1 siRNA experiment LVN treated cells as in the 
PGR siRNA experiment was unexpected. Nonetheless there are reports of ERα and PGR 
signaling inducing a strong proinflammatory response in ovariectomized mice, which 
could represent a similar, hormone depleted situation (Calippe et al., 2010) (Houdeau et 
al., 2007).  
Furthermore, a genomic analysis in breast cancer cells showed positive crosstalk between 
NF-κB and ER to be significantly more probable than negative  (Frasor et al., 2009). As 
the use of DCC medium increased the inflammatory response of THP1 cells and produced 
notable variance in viability (fig 14), a hormone depleted cell culture was not seen as a 
good base for these experiments. 
3.5 Anti-inflammatory PGR signaling in monocytes could alleviate intestinal 
inflammation by reducing IL-6, IL-1β and TGFβ 
In conclusion, the silencing experiments possibly indicate a mixed inflammatory effect 
of both receptors, with PGR being a stronger anti-inflammatory influence while ERα 
might induce a weak proinflammatory effect. Several different directions of 
immunomodulating properties of ovarian hormones can be found in the literature, and it 
is not clear what causes this discrepancy. All animal experiments should verify the serum 
hormone levels and receptor expression levels when investigating immune modulation 
by ovarian hormones and ideally the experiments would be as far standardized as possible 
in order to untangle the underlying cause of all the variance in the results.  When 
conducting in vitro research, origin of the cells should be considered carefully. Cell line 
monocyte immune response is not identical to primary CD14+ monocytes, as seen in 
figures 15 and 16. 
The results presented here may indicate that upregulation of ERα may induce 
proinflammatory signaling and LPS decreases ERα expression, possible as a negative 
feedback mechanism. OVX has been observed to upregulate ERα protein in neuronal 
tissue and similarly high dose estrogen to decrease receptor expression (Liu, X. and Shi, 
2015). Although many studies have addressed the effect of ERα mediated signaling, there 
are no reports on the association of high ERα levels with increased immune responses.  
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PGR agonist LVN has showed the most consistent anti-inflammatory effects in this 
project. It might be possible that PGR signaling in monocytes could beneficially modulate 
gut inflammation through a tissue damage reducing effect, as it reduces TGFβ, IL-1β and 
IL-6 expression in primary human CD14+ monocytes ex vivo. These cytokines are 
involved in Th1 and Th17 differentiation and secretion of Th17 secretion of IL-17 and 
IL-21 in the gut (Zhou et al., 2007) (Pelletier et al., 2010). Further, according to the results 
presented here ERα upregulation is proinflammatory and induces an increase in the 




4. Materials and methods 
To study the role of ERα, ERβ, and PGR on myeloid cell signaling, cell culture 
experiments were performed using THP1-Lucia (InVivogen) cell line as well as human 
primary monocytes. Small interfering RNA-based silencing was utilized to temporarily 
knock-down ERα and PGR. Cells were then cultured with SERMs or other steroid 
hormone receptor ligands, to distinguish the effect of ERα and PGR receptor signaling on 
immune response of monocytes. NF-κB activity assay was accompanied by a 
fluorometric viability assay, performed on THP1-Lucia cells. THP1-Lucia and primary 
monocyte gene expression of pro- or anti-inflammatory cytokines was analyzed using 
RT-qPCR. All experiments include a vehicle control including consistent concentration 
of diluent of the lipophilic pharmaceuticals, as well as a control for immunogenic stimuli. 
These cells have been treated with 0,1% DMSO or 0,1% DMSO together with consistent 
levels of LPS or TNFα. 
4.1 Pharmaceuticals 
To study the effects on ER and PGR ligands estradiol (Sigma), levonorgestrel and 
mifepristone (Tocris) were used, as well as selective estrogen receptor modulating drugs 
RAL and fulvestrant (Sigma) and a novel compound produced by Forendo Pharma Ltd., 
referred to here as SERM2 (table 5). If not stated otherwise, SERM, RAL, LVN and MFP 
were used in 1 µM concentrations, and E2 in 10 nM. 
 
 
4.2  Line cell culture 
All cell culture reagents were of the Gibco® product line (ThermoFisher, USA), unless 
mentioned otherwise. THP1-LuciaTM NF-κB reporter monocytes(InVivogen, USA) were 
cultured at 37˚C and 5% CO2 in RPMI-1640 media without phenol red and supplemented 
Table 5. Target, function and used abbreviations of the compounds used. 
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with 1x GlutaMAXTM, 4.5 g/l glucose, 10mM HEPES and 1mM sodium pyruvate, 10% 
iFBS-EU and 50 μg/ml Pen-Strep for up to 20 passages. The cells were subcultured every 
3-7 days and to every other passage ZeocinTM (InVivogen, USA) was added for reporter 
selection. MCF-7 cells were cultured to 90 % confluency at 37˚C and 5% CO2 in αMEM 
without phenol red, with 10% iFBS-EU, 1x GlutaMAXTM, 25 μg/ml Pen-Strep and 10 
nM estradiol.  
4.3  Dextran-coated charcoal treated iFBS 
iFBS was stripped of hormones by dextran coated active charcoal, including 0.25% 
charcoal (Merck), 0.0025% dextran 170 (Sigma), 0.25 M sucrose (SigmaUltra, Sigma), 
1,5 mM MgCl2 hexahydrate (J.T Baker) and 10 mM HEPES (Gibco). The dextran-
charcoal solution was incubated at 4°C overnight and then pelleted (500 x g, 10 min) and 
washed with sterile H2O before suspended into an equal amount of iFBS-EU and 
incubated 2 x 45 min at 56°C. The solution was pre-filtered using a 0.45 mm filter and 
filtered sterile through a 0.22 mm filter. 
4.4 NF-κB activity assay  
NF-κB activity assay was performed using THP1-Lucia (InVivogen) NF-κB reporter 
cells, with integrated NF-κB-inducible Luc reporter construct. The cells secrete luciferase 
into culture media. 
Ligand modulation of TNFα response was performed with cells plated at 100 000 cells 
per well (n=5). ER and PGR ligands (1 nM-3μM) were added to the wells and incubated 
48 hrs. TNFα (5 ng/ml) was added to the wells and incubated overnight.  
Silencing of the ESR1 and PGR was performed with HiPerfect tranfection reagent 
(Qiagen) and Silencer ® validated siRNAs (Ambion® Life Technologies) for ESR1, PGR 
and a scramble siRNA as a negative control. For the transfection mix, serum-free media 
was used. 112.5 ng/well (150nM) of siRNAs and 1.8 µl/well HiPerfect were incubated at 
RT for 5-10 min and siRNAs were transfected at 150 nM for 6 h, then diluted to 50 nM 
and incubated overnight. Transfected THP1-Lucia cells were plated at 60 000 cells per 
well, n=5. ER and PGR ligands (1μM) were added to the wells and left to incubate 
overnight. TNFα (5 ng/ml) was added to the wells and left again overnight.  
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For measuring accumulated NF-κB induced luciferase secretion, 10 µl of cell culture 
media was taken from the wells and transferred to an optical microplate. Luminescence 
was measured with a Victor x4 plate reader (1420, Perkin-Elmer) with a liquid dispenser 
(DISPENCER for 1420, 1420-2560, Perkin-Elmer). 50 µl Quanti-Luc solution was 
injected before a 4 s measurement. The luciferase reaction results were related to those of 
a fluorometric viability assay. 
4.5  Viability assay 
The luciferase reaction results were related to those of a fluorometric viability assay. 
alamarBlue™ Cell Viability Reagent (Invitrogen™, ThermoFisher) was used according 
to the instructions provided by the manufacturer and measured using excitation at 550 nm 
and emission at 580 nm wavelength in a Hidex Chameleon multiplate reader (Perkin-
Elmer).  
4.6  RT-qPCR 
To verify the siRNA silencing effect by RT-qPCR 300 000 cells/sample were incubated 
with transfection mix as described in the NF-κB activity assay.  
For cytokine expression analysis THP1-Lucia cells were plated at 100 000 cells/well 
(n=4) and incubated with ER and PGR ligands overnight. Cells were then stimulated with 
LPS (10 ng/ml) and incubated again, overnight. Expression was measured first in non-
silenced cells, and later in ERα or PGR silenced human primary CD14+ monocytes. For 
these experiments, cells were plated at 300 000/well (n=1-4) and incubated overnight 
with ER and PGR ligands before stimulation with 10ng/ml LPS (8 h). 
Cells were lysed using a guanidinium thiocyanate buffer with 1% β-mercaptoethanol, and 
RNA was extracted using NucleoSpin® RNA extraction kit (Macherey-Nagel) and 
reverse transcription was performed by High Capacity Reverse Transcription Kit 
(ThermoFisher). Cytokine expression analysis was performed by TaqMan® Gene 
Expression Assays (ThermoFisher) using ACTB as reference gene. All steps were 





4.7  Western blot 
For Western blot analysis of the siRNA treatment, 106 cells/sample were incubated with 
transfection mix (serum-free medium, siRNA and HiPerfect transfrection reagent for 6 h 
in 150 nM and overnight in 50 nM siRNA (negative control, ESR1 and PGR). Cells were 
lysed 24h after transfection in RIPA buffer and stored at -80°C. Proteins were quantified 
by Pierce BCA Protein Assay Kit (ThermoFisher), according to manufacturer’s 
instructions and all samples were standardized to 50 µg total protein/lane. SDS-PAGE 
separated proteins were transferred (100 V, 1 h) by a wet-transfer system (Mini Trans-
Blot® Cell, PowerPac™ and Basic Power Supply, Bio-Rad) onto PVDF membrane 
(Amersham™ Hybond® P Western blotting membranes, pore size 0.2 μm, Sigma) and 
blotted with primary antibodies Human/Mouse/Rat ER alpha /NR3A1 (R&D Systems) 
and Progesterone Receptor Antibody (MA1-410, Thermo) . Secondary Rabbit Anti-
Mouse IgG H&L (HRP) (abcam) and detected using SuperSignal West Pico 
Chemiluminescent Substrate (TermoFisher) and LAS-4000 (Fujifilm Life Science) or 
Sapphire Biomolecular Imager (Azure Biosystems). The blot was analyzed using 
quantification of histogram area in ImageJ (Schneider et al., 2012). 
4.8 Extraction and silencing of CD14+ human primary cells 
For monocyte extraction, blood was drawn from one healthy human volunteer (adult 
male) to lithium-heparin tubes (Lithium Heparin Tube for Blood Collection, Henso 
Medicals) on three separate occasions. The peripheral blood mononuclear cells were 
separated by Fiqoll centrifugation technique and antibody labeled magnetic beads for 
CD14+ cells (MACS® Cell Separation, CD14 MicroBeads, human, Miltenyi Biotec). 
Cells were cultured at 37˚C and 5% CO2 in αMEM without phenol red supplemented with 
10% iFBS-USA, 0,05% glutamine and 50 μg/ml Pen-Strep. For ERα and PGR silencing,  
siRNA transfection mixes for negative control, ESR1 and PGR (serum-free medium, 
siRNA and HiPerfect transfrection reagent x µl/well) was added after extraction (6 h at 
150 nM and overnight in 50 nM siRNA concentrations). All CD14+ monocytes were 
activated with 50 ng/ml IFNγ overnight.  
 
 
4.9 Statistical analysis 
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Level of significance was set to P≤0.05 and statistical significance is marked by asterisk 
(P≤0.05 *, P≤0.01 **, P≤0.001 ***). All statistical analysis was performed in Prism8 
(GraphPad Software, Inc). Analysis of variance was tested by one- or two-way ANOVA 
for normally distributed data, while non-parametric Kruskal-Wallis test was used for 
analysis of non-normally distributed data. All analysis of variance was followed by a 
suitable post-hoc test. Dunnett's multiple comparisons test was used for analyzing 
difference to control, while Tukey´s or Sidak´s multiple comparison test was used for 
analyzing significant differences between all groups. 
4.10 Ethical and confidentiality issues 
Blood samples acquired for primary human CD14+ cell culture was taken by a licensed 
health care professional in accordance to the permission to collect and use human 
mononuclear cells from healthy volunteer donors for in vitro studies (Turku University 
Ethics Committee, statement 6/2017). No other personal information was stored, except 
for the sex and the age of the donor. The sample was not used for any other purposes, 
than this study project. SERM2 is a pharmaceutical compound under development by 
Forendo Pharma Ltd and thus the structure is strictly confidential. 
5. Acknowledgements 
Sincere thanks to our PI Jorma Määttä and Dr. Lauri Polari for providing scientific 
supervision of the thesis work and for transferring knowledge. I would also like to 
acknowledge DDD Professor Ullamari Pesonen and University Teacher Dr. Sanna Soini. 
Special thanks also to Forendo Pharma Ltd for the experimental pharmaceutical. 
Additionally, I would like to acknowledge all the help and guidance provided by 




6. Appendices  





7. List of used abbreviations 
AF    Activation function 
APC    Antigen presenting cell 
Arg    Arginase 
CCR2    C-C chemokine receptor 
CD    Cluster of differentiation 
CD     Crohn´s Disease 
CX3CR1 C-X3-C Motif Chemokine 
Receptor 1 
DSS Dextran sodium sulphate 
E1    Estrone   
E2    Estradiol 
E3    Estriol 
E4    Estrone 
ER    Estrogen receptor (protein) 
ERE    Estrogen response element 
ESR    Estrogen receptor (gene) 
FSH    Follicle stimulating hormone 
GPER G protein-coupled estrogen 
receptor 
IBD    Inflammatory bowel disease 
IL    Interleukine 
IκB    Inhibitory kappa B 
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iNOS    inducible nitric oxide synthase 
KO    Knockout 
LH     Luteinizing hormone  
LPS    Lipopolysaccharide 
LVN    Levonorgestrel 
Ly    Lymphocyte antigen 
MPF    Mifepristone 
NF-κB Nuclear factor kappa-light-chain-
enhancer of activated B cells 
OVX    Ovariectomized 
PGR    Progesterone receptor 
PI3K    Phosphatidylinositol-3-Kinase 
SERM Selective estrogen receptor 
modulator 
siRNA    small interfering RNA 
Th    T helper (cell) 
TIF2 Transcriptional Intermediary 
Factor 2 
TLR    Toll-like receptor 
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